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ABSTRACT 
Central nervous system (CNS) tumors are the most common form of solid tumor in 
children and young adults. Medical advancements have increased survival rates 
dramatically for people diagnosed with CNS tumors, but long-term disease- and 
treatment-related sequelae remain significant issues for survivors. The chronic health 
conditions and vulnerability to late effects that this population of survivors experiences 
are different from that of survivors of other forms of cancer due to the nature and location 
ofCNS tumors. Health-related quality oflife (HRQoL) measurement has become a 
useful and significant tool for tracking the progress and well-being of patients long-term. 
This paper examines HRQoL specifically for adolescents and young adults (AYA) who 
are CNS tumor survivors, and describes the findings of a research study conducted to 
develop the Health Related Quality of Life Evaluation in Survivorship of CNS Tumors 
(QUEST CNS) instrument. 
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METHODS: 
Five focus groups were conducted with 19 AYA survivors ofCNS tumors in November 
and December 2010. Transcripts were coded and analyzed to identify the major domains 
ofHRQoL to be included in the QUEST CNS instrument being developed. Separately, a 
review of existing HRQoL instruments was conducted to identify major domains in the 
literature and these instruments. 324 potential items were generated from the focus group 
findings and instrument review, and the list was electronically rated by a group of 8 
experts in the fields of psychology, oncology, and hematology. Content validity ratios 
were determined for each item, and the list of items was amended accordingly. 165 items 
were removed, leaving 159 items for the preliminary QUEST CNS instrument. 
RESULTS: 
Focus Group Findings: The major domains ofHRQoL for A YA survivors of CNS tumors 
were identified as: 1) Physical Health and Well-Being, 2) Cognitive Functioning, 3) 
Mental Health and Well-Being, 4) Social Well-Being, 5) Reproduction and Sexual 
Health, and 6) Support Systems. 
Review of Existing Instruments: We included 19 instruments in our analysis that 
measured HRQoL, health status, and/or function in patients. We found that none of the 
existing instruments adequately covered the domains identified in our focus groups, 
including those instruments designed specifically for patients with brain tumors. 
VI 
Instrument Development: The preliminary QUEST CNS instrument includes 159 items 
across the six domains identified in the focus groups. 
CONCLUSIONS: 
Currently there are no qualitative tools that can comprehensively capture the unique 
HRQoL experiences of A Y A survivors of CNS tumors. The QUEST CNS instrument, 
although preliminary, has the potential to fill a gap in HRQoL measurement. Future 
studies should focus on fmalizing the instrument and on psychometric testing in order to 
determine validity and reliability of the instrument. 
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INTRODUCTION 
Tumors of the central nervous system (CNS) are the most common type of solid 
tumors in children in the United States (CBTRUS Report, 2012). Medical advancements 
have contributed to a growing survival rate among pediatric CNS tumor patients, with the 
most recent ten-year survival rate among children being 68.6% (CBTRUS, 2011). 
Morbidities related to the disease and treatment sequelae, however, are common, and 
vary by the age at diagnosis, type of treatment(s) received, and the histopathology of the 
tumor. Complete craniospinal radiation therapy in combination with surgery and/or 
chemotherapy is the current standard of care for most CNS tumors. The nature of the 
disease and the invasive treatments that CNS tumors require place survivors at increased 
risk for developing neurocognitive deficits, sensory problems, psychosocial difficulties, 
learning disabilities, endocrine disorders, pulmonary disease, poor reproductive health, 
and other chronic conditions. Late effects that surface years after diagnosis and treatment 
are also quite common. Collectively, these morbidities have the potential to affect the 
overall health and well-being of survivors. 
Existing studies on cancer and CNS tumors have shown that the morbidities 
related to CNS tumors and treatment sequelae have the potential to impact the physical 
and neurocognitive functioning of survivors. A report from the Childhood Cancer 
Survivor Study, for example, showed that pediatric cancer survivors were more likely to 
experience adverse health outcomes, mental health, functional impairment, and activity 
limitations when compared to sibling controls (Hudson, et al., 2003). Continuous 
surveillance of the health-related quality of life (HRQoL) of survivors is one valuable 
way to measure the health of CNS tumor survivors long-term. HRQoL encompasses the 
physical and mental well-being of an individual, including a person's ability to perform 
activities of daily living, functional skills, physical abilities, health status, social support, 
cognition, behavior, and mental health. Several HRQoL assessment tools currently exist 
for pediatric and adult patients with various health conditions, including those with 
cancer and brain tumors. 
There is currently no instrument, however, that captures the experiences of CNS 
tumor survivors during adolescence and young adulthood. This population of survivors 
has different needs from their pediatric and older adult counterparts because of the 
transitional nature of their age group. This includes, for example, the changes in 
psychosocial support, medical and financial resources, and reproductive status that occur 
with the transition from childhood to adulthood. Additionally, many of the instruments 
designed for cancer survivors and cancer patients fail to capture the unique 
neurocognitive sequelae that often affect survivors of CNS tumors. 
With support from the Lance Armstrong Foundation, we developed the Health 
Related Q!!ality of Life Evaluation in ~urvivorship of CNS Tumors instrument (QUEST 
CNS), which is specifically aimed at adolescent and young adult (A Y A) survivors. Our 
instrument was informed by focus groups conducted with A Y A CNS tumor survivors 
from Massachusetts and an expert panel of medical providers that included oncology 
nurses, pediatric oncologists, pediatric interventional radiologists, and other specialists in 
the field of CNS tumors. By developing a new targeted tool that is able to capture the 
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broad spectrum of potential HRQoL issues for this population, we believe that we will be 
able to better identify the needs of survivors long-term. Such information will be 
invaluable in improving the quality of care delivered to both patients and survivors of 
CNS tumors . 
About CNS Tumors 
Central nervous system (CNS) tumors include malignant and benign tumors that 
originate in the brain, spinal cord, or meninges. As of2004, an estimated 612,000 people 
living in the United States had the diagnosis of a primary brain or CNS tumor (CBTRUS 
-Fact Sheet, 2011). Of those, approximately 124,000 were malignant tumors and 
488,000 were non-malignant tumors. Among children, the most recent prevalence rate for 
CNS tumors is 35.4 per 100,000, which estimated that 28,844 children were living in the 
United States with that diagnosis in 2004 (Porter et al., 2010; CBTRUS- Fact Sheet, 
2011). 
The majority ofCNS tumors originate in the brain and are commonly referred to 
as "primary brain tumors." CNS tumors also encompass lymphoma, ependymomas, 
meningiomas, germ cell tumors, and oligodendrogliomas (Fisher, et al., 2008). Among 
children, primary brain tumors are the second most common malignancy (American 
Brain Tumor Assocition, 2011 ). Pilocytic astrocytomas, medulloblastomas, and 
brainstem gliomas are the most frequently seen CNS tumors in children (Goljan, 2010). 
The cerebellum, brain stem, temporal lobe, frontal lobe, parietal lobe, ventricle, and 
cerebrum account for 16.7%, 10.7%, 6.9%, 6.0%, 3.0%, 5.8%, and 5.6% ofCNS tumor 
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sites among children ages 0-19 years, respectively (CBTRUS- Report, 2012). Tumors of 
the meninges account for less than 3% of all pediatric CNS tumors, while the spinal 
cord/cauda equine and cranial nerves account for 4.8% and 6.2% of childhood CNS 
tumor sites, respectively. 
Although primary brain tumors are the second-leading cause of cancer-related 
deaths among children after leukemia, the overall survival rate among children with CNS 
tumors is generally high, with an estimated five-year survival rate of72.6% for people 
diagnosed at ages 0 to 19 years (American Brain Tumor Association, 2011; CBTRUS-
Fact Sheet, 2011). Survival rates have been shown to be significantly affected by the 
volume, location, and type of tumor (Heimans & Taphoom, 2002). 
The incidence and survival rates among people diagnosed in adolescence and 
young adulthood differ from those found in pediatric populations with CNS tumors. 
Among people 15 to 29 years, CNS tumors accounted for 6% of neoplasms between 1975 
and 1998 in the United States (Bleyer et al., 2006), which is significantly different from 
pediatric incidence rates. Although the A Y A population encompasses the age range of 15 
to 40 years, the group is often separated into adolescent and young adult age groups. This 
is likely due to the proposed differences in incidence, clinical presentation, and survival 
rates between adolescents and young adults with CNS tumors. The' overall ten-year 
survival rate for CNS tumors, for example, is more than 50% for patients diagnosed at 
less than 20 years, while survival rates progressively decrease for patients diagnosed at a 
later age (Bleyer et al., 2006) . Additionally, it has been proposed that the onset of 
pubertal changes, cessation of brain growth, and the onset of brain aging place people in 
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the A Y A years at risk for specific types of CNS tumors during those physiological 
changes in their life (Walker et al., 2005). The incidence of CNS tumors from 1975 to 
2000 was 19.2 per year per million for ages 15 to 19 years; 21 .2 per year per million for 
ages 20 to 24 years; 27.0 per year per million for ages 25 to 29 years; 33 per year per 
million for ages 30-34 years; 39.8 per year per million for ages 35-39, and 49.3 per year 
per million for ages 40 to 44 years. Of note, the incidence of spinal cord tumors decreases 
with age from birth to 40 years. Figure 1 is a graph from the National Cancer Institute's 
Surveillance Epidemiology and End Result A Y A Monograph that depicts the incidence 
rates of CNS tumors by age and tumor type as outlined by the International Classification 
of Childhood Cancer (I CCC) (Bleyer, 2006). 
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Figure 1 Incidence rates ofCNS tumors by age and ICCC classification from 1975 to 
2000 in the United States. Taken from Bleyer et al. , 2006, p. 70. 
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Longitudinal trends in survival rates are also different between pediatric and A Y A CNS 
tumor patient populations. Childhood survival rates, for example, have risen dramatically 
over the past several years, but there has been only a marginal increase in survival rates 
among A Y A patients with CNS tumors (Hampton, 2005). Five- and ten-year survival 
rates by histology of the tumor are shown in Table 1 for children and A Y A populations 
(CBTRUS- Table 24, 2012). 
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Table 1 Five- and Ten-Year Survival Rates for Malignant CNS Tumors Diagnosed in 
Individuals Ages 0-44 Years by Histologya Table adapted from CBTRUS- 2012 CBTRUS 
Statistical Rep_ort Tables, 2012. 
Histolof(Y Age No. o[Cases 5-Year 10-Year 
Pilocytic astrocytoma 
0-19 years 1,830 96.6% 95.1% 
20-44 years 543 90.8% 86.5% 
Protoplasmic & fibrillary astrocytoma 
0-19 years 127 84.7% 80.2% 
20-44 years 281 59.7% 42.0% 
Anaplastic astrocytoma 
0-19 years 225 33 .2% 28.1% 
20-44 years 1,013 49.2% 34.7% 
Astrocytoma - not otherwise specified 
0-19 years 572 82.1% 79.5% 
20-44 years 1,235 65.1% 45.9% 
Glioblastoma 
0-19 years 259 19.4% 14.0% 
20-44 years 2,227 16.6% 9.8% 
0 ligodendroglioma 
0-19 years 199 92.4% 89.4% 
20-44 years 1,390 85.2% 67.4% 
Anaplstic oligodendroglioma 
0-19 years 31 b b 
20-44 years 429 64.8% 45.8% 
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Table 1 Five- and Ten-Year Survival Rates for Malignant CNS Tumors Diagnosed in 
Individuals Ages 0-44 Years by Histologya Table adapted from CBTRUS- 2012 CBTRUS 
Statistical Rep_ort Tables, 2012. 
Histolo!JJ!.. Ag_e No. o[Cases 5-Year 10-Year 
Ependymoma/anaplastic ependymoma 
0-19 years 566 72.9% 64.5% 
20-44 years 629 91.3% 88.4% 
Mixed glioma 
0-19 years 103 82.0% 75.5% 
20-44 years 774 68.2% 54.4% 
Glioma malignant - not otherwise specified 
0-19 years 1,805 57.1% 55.8% 
20-44 years 599 64.6% 49.0% 
Malignant neuronal/glial, neuronal and mixed 
0-19 years 125 70.8% 66.2% 
20-44 years 147 77.8% 67.6% 
Embryonal/primitive/medulloblastoma 
0-19 years 1,502 61.6% 56.4% 
20-44 years 436 66.6% 57.4% 
Lymphoma 
0-19 years 60 71.7% 63 .9% 
20-44 years 949 27.0% 20.7% 
All Brain and CNS Tumors 
0-19 years 7,546 72.6% 68.6% 
20-44 years 11,400 57.1% 45.5% 
a Data obtained from Surveillance Epidemiology and End Results (SEER) Registries, 1995-
2008 
6 Sample size too small 
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Pathology of CNS Tumors 
CNS neoplasms include primary and secondary tumors that arise anywhere within 
the brain, spinal cord, or meninges. Due to their location, CNS tumors can have 
detrimental consequences for the patient due to the fragility of the vital structures 
surrounding them. The potential severity of disease-related morbidities is a significant 
difference between neoplasms in the CNS and those that originate elsewhere in the body 
(Kumar et al. , 2003). CNS tumors generally fall within three major histologic categories: 
gliomas, meningiomas, and medulloblastomas. Gliomas are tumors that affect the 
neuroglial cells that support the CNS. Astrocytomas, ependymomas, and oligodendromas 
are all considered sub-types of gliomas. Meningiomas are tumors that arise out of 
meningothelial cells, which make up the outer membranes of the CNS. Medulloblastomas 
are embryonal small cell tumors that are seen almost exclusively in children. CNS tumors 
that do not fit into these three categories include intraprenchymal neoplasms such as 
primary CNS lymphoma and germ-cell tumors; Ganglion cell tumors; and secondary 
(metastatic) CNS neoplasms. 
The prognosis and biology of the tumor are highly dependent on the grading of 
the CNS tumor, which considers the tumor's morphology, mitotic activity, and vascular 
proliferation (Kumar et al., 2003). The World Health Organization's (WHO) 
classification of CNS tumors is widely used to grade CNS neoplasms. Tumors are graded 
on a scale from I-IV, with I being the lowest and IV being the highest and most severe. 
Low-grade tumors tend to by cystic and non-invasive of surrounding tissue, while high-
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grade tumors are generally well-differentiated, diffuse, and malignant. Below are detailed 
descriptions of the three most prevalent CNS tumors in children (Goljan, 2010). 
Pilocytic astrocytoma 
Pilocytic astrocytomas are grade I tumors that are primarily seen in children and 
young adults less than age 20 years. They may occur anywhere within the CNS where 
astrocytes are present, but most frequently arise in the cerebellum, hypothalamic region, 
optic nerves, and posterior fossa (Wallner et al., 1988; Kumar et al., 2003). These 
astrocytomas tend to be slow-growing and benign. Noninvasive pilocytic astrocytomas 
are candidates for complete surgical resection due to their cystic nature. The five-year 
survival rate among patients who undergo complete surgical resection of their 
astrocytoma is close to 1 00%, and patients in this group rarely develop secondary 
neoplasms (Fernandez et al., 2003; Villarejo et al2008). Tumors located in the 
hypothalamus and posterior fossa, however, are less accessible, which inhibits complete 
surgical resection. Pilocytic astrocytomas that are invasive, that can only be partially 
resected, or that are located in the optochiasmic region generally have a poorer prognosis, 
with an estimated five-year survival rate of92% (Fernandez et al., 2003). Overall 
survival among patients with pilocytic astrocytomas is quite high, and survivors have 
been shown to rate their HRQoL similarly to healthy controls and to perform activities of 
daily living age-appropriately (Zuzak et al., 2008). Children with pilocytic astrocytomas 
are most at-risk for developing neurological deficits such as ataxia and disequilibrium; 
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cognitive deficits; behavioral and emotional problems; and motor problems (Zuzak et al., 
2008; Daszkiewicz et al., 2009). 
Medulloblastoma 
Medulloblastomas are primitive neuroepithelial neoplasms that are made of 
embryonal small cells (Kumar et al., 2003). 70% of medulloblastomas occur in children 
ages 1 to 10 years, with the remainder occurring in adolescents or older adults. A 
mutation of chromosome 17 occurs in approximately one third to one-half of all pediatric 
medulloblastomas, suggesting a genetic component to their development (Hinz et al., 
2006). Among pediatric cases, medulloblastomas tend to grow rapidly and arise at or near 
the vermis, which connects the cerebral hemispheres of the brain (Kumar et al. 2003; 
Hinz et al., 2006). Unlike astrocytomas, medulloblastomas have the ability to spread 
through the cerebral spinal fluid (CSF), which can lead to CSF obstruction, increased 
intracranial pressure, and metastatic deposits (Kumar et al., 2003). This phenomenon 
places meduolloblastoma patients at risk for CSF-related problems and motor deficits 
such as gait and posture abnormalities (Johnson et al., 1994; Muzumdar et al. , 2011). 
Long-term quality of life studies have shown that survivors developed 
neuropsychological and neurological deficits, including lower IQ, decreased perceptual-
motor task performance, and poor motor dexterity (Johnson et al, 1994). Children who 
were diagnosed before age 3 years had a lower IQ on average than those who were older 
at age-of~diagnosis (Johnson et al., 1994). Survivors are also susceptible to severe 
cognitive and endocrine problems as a result of their treatment with radiation and 
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chemotherapy (Massimino et al., 2012). As seen in Table 1, five- and ten-year survival 
rates for pediatric medulloblastomas are 61.6% and 56.4%, respectively. 
Brainstem Glioma 
1 0% of all pediatric brain tumors are brainstem gliomas, which includes all 
tumors originating in that region (Ueoka et al., 2009). Brainstem gliomas are classified by 
anatomic location into intrinsic pontine, tectal, and cervicomedullary tumors (Landolfi & 
Venkataramana, 2011). Tectal and cervicomedullary tumors have better prognoses than 
intrinsic pontine gliomas, but all brainstem gliomas are associated with high rates of 
morbidity and mortality that near 100% (Ueoka et al. , 2009; Landolfi & Venkataramana, 
2011 ; Kivivuori et al. , 20 11 ). Palliative care and radiation therapy are the current 
standard of care for pediatric patients with brainstem gliomas. Since there is no known 
curative treatment of brainstem gliomas, medical care aims to prolong survival and 
optimize quality of life during that time period. 
Clinical Treatment of CNS Tumors 
The current standard of care for CNS tumors consists of surgery, chemotherapy, 
radiation therapy, or some combination of those treatments. Malignancy, stage, location, 
and grade of the tumor are the primary factors considered when making a care plan. 
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Surgery 
Complete surgical resection of the tumor is curative in most cases ofbenign 
tumors. In cases of malignant tumors or partial resection, surgery enables biopsy of the 
tumor, histologic and biological analysis of the resected tissue, and a temporary reduction 
in symptoms that can provide pain relief and adequate time to deliver other forms of 
treatment (Buckner et al., 2007). Since surgery can provide both diagnostic and 
therapeutic benefits, it is often the first treatment given to CNS tumor patients. Damage 
to some of the normal tissue surrounding the tumor, however, is inevitable. The 
preservation of neurological function is paramount, especially for tumors located in vital 
areas of the brain. In these cases, only a biopsy of the tumor is obtained in order to inform 
decisions for radiation therapy and chemotherapy. The recent advent of neuroanesthesia 
and stereotactic surgery has helped minimize neurological sequelae. N euroanesthesia 
enables patients to stay awake during the surgery and helps surgeons to identify the 
neurological functions linked to the tissues that surround the tumor. Stereotactic surgery 
provides surgeons with three-dimensional robotic guidance, enabling them to more 
accurately locate and access the tumor (Buckner et al., 2007; Kanner et al. , 2002; Wu, 
Zhou, et al., 2007; Roth et al., 2006). Stereotaxis is also useful for tumor ablation during 
radiosurgery, as it can identify an optimal path of delivery and increase the precision of 
radiation administration (Buckner et al., 2007). 
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Radiation Therapy 
Radiation therapy is therapeutically appropriate for tumors that cannot be resected 
completely, that have microscopic tumor spread, or that cannot be destroyed through 
chemotherapy alone (Kirsch & Tarbell, 2004). Radiation therapy works by causing 
damage to the deoxyribonucleic acid (DNA) of the cancerous cells through direct 
radiation or through the creation of free radicals that subsequently cause DNA mutations 
(National Cancer Institute, n.d.). Conventional radiation therapy consists of 
administration ofx-rays, gamma rays, or protons to the tumor in order to kill or inhibit 
the growth of neoplasm (Kirsch & Tarbell, 2004). Radiation doses are measured in units 
of gray (Gy), which indicates the amount of radiation energy absorbed by one kilogram 
of human tissue (National Cancer Institute, n.d.). Dosing depends on the tumor type, as 
certain cells require more irradiation than others to be affected. The two primary modes 
of radiation delivery are external-beam and internal-bean radiation therapy. External 
beams are emitted from a machine outside the body, while internal beams are delivered 
through radioactive materials injected or placed inside the body of the patient. Both forms 
of delivery carry significant risks to the patient, as radiation therapy is not selective and 
elicits DNA damage to normal tissue that lies on the entry and exit path of the radiation 
beams. 
Known sequelae of radiation therapy include endocrine disorders, neurocognitive 
deficits, sensory deficits, learning disabilities, late restrictive lung disease, and radiation-
induced neoplasms (Yock & Tarbell, 2004; Twombly, 2009; Bhatia et al., 2007). Some 
sequelae have a dose-dependent association with irradiation of specific regions of the 
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brain. Temporal irradiation, for example, is associated with memory impairment, while 
frontal region irradiation is associated with decreased motor function (Armstrong et al., 
2010). Patients who received radiation therapy for CNS tumors are also at risk for 
incurring damage to their hypothalamic-pituitary axis, leading to endocrinopathies that 
affect metabolism, weight, bone density, puberty, growth, and reproduction (Constine, et 
al., 1993; Lustig et al., 2003; Leung, et al., 2005). For pediatric patients, the age at which 
a person receives craniospinal radiation therapy is a significant factor in the treatment 
plan, as patients exposed to radiation at an earlier age tend to have a higher incidence and 
severity of side effects than patients treated at an older age (Leung, et al., 2005; Yock & 
Tarbell, 2004). 
The development of high-resolution brain imaging through computed tomography 
(CT) and magnetic resonance imaging (MRI) has led to new techniques that improve the 
accuracy of radiation delivery and thereby minimize damage to normal tissue. Conformal 
radiation therapy constitutes any delivery technique that "conforms" the radiation dose to 
the tumor target. CT and MRI are crucial for conformal radiation therapy, as they enable 
the tumor to be accurately located and defined within the CNS (Y ock & Tarbell, 2004; 
Kirsch & Tarbell, 2004). By obtaining the volume and location of the tumor, providers 
can determine the minimal radiation dose needed to affect the tumor and can consider the 
tolerance of the surrounding normal tissue to that dose prior to treatment (Kirsh & 
Tarbell, 2004; Leung et al., 2005). Improvements in craniospinal immobilization have 
also reduced damage to normal tissue by enabling providers to direct radiation beams 
along the same exact path for every treatment (Nevinny-Stickel et al., 2004; Kooy et al., 
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1994; Hurkmans et al., 2001 ). The use of proton radiation therapy has also been 
beneficial in preserving brain function. Unlike traditional photon therapy, proton 
radiation beams have a low entrance dose to normal tissues and the energy of the beam 
falls off by the end of the tumor. Since the proton beam cannot penetrate past the tumor, 
normal tissues that lie along the usual exit path of the beam are preserved (Y ock & 
Tarbell, 2004). Additionally, since several proton beams need to be layered upon one 
another in order to generate enough energy to reach the tumor, the minimal dose required 
to penetrate the tissue can be determined. This method is in comparison to photon beams, 
which are delivered at a maximal dose and subsequently lose energy as they exit the body 
(Yock & Tarbell, 2004). 
Chemotherapy 
Chemotherapy involves the use of cytotoxic drugs to target and destroy cells that 
rapidly reproduce. The loss of normal growth controls is characteristic of neoplastic cells, 
and therefore chemotherapy is very effective at targeting tumor cells. Chemotherapy, 
however, may also affect other rapidly proliferating cells such as those found in the 
bowel, bone marrow, hair follicles, and mouth (American Cancer Society, 2011). 
Chemotherapy drugs generally fall into the major categories of alkylating agents, 
antimetabolites, anthracyclines, topoisomerase inhibitors, mitotic inhibitors, and 
corticosteroids (American Cancer Society, 2011). Typically, chemotherapy destroys 
neoplastic cells through the inhibition of cell growth and proliferation, disruption of DNA 
binding proteins, DNA intercalation, induction of apoptosis, generation of free radicals, 
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and inhibition of angiogenesis and vascularization of the tumor (American Cancer 
Society, 2011). 
Chemotherapy is often used as an initial treatment for young pediatric patients 
with CNS tumors because the incidence and severity of its side effects are not as closely 
correlated with the age-at-treatment as sequelae for surgery and radiation therapy (Kellie, 
1999). Chemotherapy, however, does carry risks for late effects such as gonadotoxicity in 
women (Blumenfeld & Eckman, 2005; Bhatia et al., 2007), cognitive impairment 
(Schagen, 2002), renal damage (Bhatia et al., 2007) and cardiac dysfunction (Carver et 
al., 2007). The goals of early chemotherapy for this age group are to delay or eliminate 
the need for other treatment modalities and to minimize the sequelae of radiation therapy 
and surgery if they are needed by reducing the size of the tumor (Pollack et al. , 1999). 
The risk of neurotoxicity from radiation therapy decreases with age, however, so for 
older children and young adults, chemotherapy is seen as a means to achieve long-term 
disease control (Pollack, et al., 1999). 
Chemotherapy is usually delivered into the bloodstream through a venous 
catheter. Alternatively, wafers of the drugs may be placed directly onto the tumor during 
surgery, leading to a highly localized dose of chemotherapy rather than a systemic one 
(Hart et al., 2008). This latter method is most often employed during the treatment of 
CNS tumors because the blood-brain barrier prevents chemotherapy agents from entering 
the CNS from the bloodstream (Muldoon et al. , 2007). 
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Survivorship, Adverse Outcomes, and Late Effects 
Survivorship among patients with pediatric cancer has risen dramatically since 
1975 because of improved access to care and advancements in treatment (Hampton, 
2005). Survivors, however, contend with lingering effects of their disease and are prone 
to the adverse late effects of radiation therapy and chemotherapy. Researchers from the 
Childhood Cancer Survivor Study estimate that 66% of survivors will have a physical 
health problem within 30 years of their cancer diagnosis, and that by age 45 years 57.1% 
and 37% of survivors will have moderate or severe health problems, respectively 
(Hampton, 2005). The risk for developing health problems is related to the type of 
treatment, age at treatment, and certain lifestyle behaviors such as risk-taking and health 
behavior (Stevens, 2005; Bellizzi et al., 2005; Pogany et al., 2006). Among cancer 
survivors, CNS tumor survivors tend to report poorer health statuses than other cancer 
survivors (Pogany et al., 2006). Among 10,397 participants of the Childhood Cancer 
Survivor Study, those with CNS tumors had the second highest risk for developing a 
chronic condition (RR 7.1, 95% CI 6.3-8.2) or a severe/life-threatening condition (RR 
12.6, 95% CI 10.3-15.5), and had the highest risk for developing 2 or more conditions 
(RR 12.4, 95% CI 1 0.5-14.6) compared to sibling controls (Oeffinger et al., 2006). 
For CNS tumor survivors, cranial and spinal radiation therapy increases the risk 
for endocrinopathies, cardiopulmonary disease, infertility, secondary cancers, 
neurocognitive problems, and motor deficits (Hudson et al., 2003; Constine, et al., 1993; 
Lustig et al., 2003; Leung, et al. , 2005; Yock & Tarbell, 2004; Twombly, 2009; Bhatia et 
al., 2007). Hudson et al. found that among survivors in the Childhood Cancer Survivor 
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Study, 44% reported adverse health status, and that survivors of childhood cancer are at 
increased risk for developing endocrine, neurocognitive, and cardiopulmonary 
morbidities related to treatment. CNS tumor survivors and cancer survivors who receive 
the multimodal treatments of chemotherapy, radiation therapy, and surgery or radiation 
therapy and surgery are more likely to report impairments in cognitive functioning than 
other cancer survivors (Pogany et al. 2006). Additionally, Pogany et al. found that these 
populations of survivors are more likely to report impaired ambulation (Pogany et al., 
2006). Survivors of pediatric brain tumors also have 29.0 times the risk for late-occurring 
stroke as sibling controls. This risk is dose-dependent for people who received cranial 
irradiation, with the highest risk of stroke occurring in those who received a cumulative 
dose of2: 50 Gy (Bowers et al., 2006). 
CNS tumor survivors overall report poorer physical health compared to other 
cancer survivors and healthy controls (Maunsell et al., 2006). A review of the Childhood 
Cancer Survivor Study revealed that 26.6% of CNS tumor survivors have poor physical 
performance outcomes and that the risk for developing deficits in physical functioning 
increased if the individual had received radiation or chemotherapy with alkylating agents 
and anthracyclines; had neurologic, cardiopulmonary, sensory, endocrine, or 
musculoskeletal morbidities; were female; or had an income of less than $20,000 per year 
(Ness et al., 2009). Similarly, a British study ofHRQoL using the Short Form 36 (SF-36) 
Health-Status Survey found that CNS tumor survivors had significantly lower physical 
health scores and were more likely to report difficulty with walking 100 yards (22%), 
bathing (21 %), and dressing (21 %) than healthy controls (5%) (Reulen et ai., 2007). 
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Some ofthe most prevalent adverse outcomes among survivors ofCNS tumors 
are behavioral and emotional outcomes. Nathan et al., found that adult survivors of 
Wilms tumor or neuroblastoma were at increased risk for adverse emotional health 
outcomes (Nathan et al., 2007). Zebrack found that survivors of brain cancer report 
significantly higher global distress and depression scores than sibling controls, but that 
type of treatment did not affect this risk (Zebrack, 2008). Similarly, Schultz et al. found 
that among adolescent survivors of childhood cancer, CNS tumor and neuroblastoma 
survivors are most at risk for developing adverse behavioral and social outcomes such as 
depression/anxiety, attention deficit, and antisocial behavior (Schultz et al., 2007). 
General studies of childhood cancer survivors have found that this population is at risk 
for experiencing long-term psychological effects such as posttraumatic stress disorder 
(Bruce et al., 2011; Taylor et al., 2012; Stuber et al., 2011; Meeske et al., 200 1), with 
those reporting lower physical and mental quality of life being most at risk (Meeske et 
al., 2001). One study also found that of3,710 adolescent cancer survivors, only those 
with childhood brain tumors were at increased risk for psychiatric hospitalization for 
psychoses, psychiatric disorders, and schizophrenia and related disorders (Ross et al., 
2003). 
Neurocognitive symptoms among CNS tumor survivors are also quite common 
and differentiate this group from other cancer survivors. A study of 165 patients with 
low-grade glioma found that 53% of those who received radiation therapy developed 
cognitive deficits such as a decline in executive functioning, information processing 
speed, or attention (Douw et al., 2009). Another study of 18 A Y A survivors of central 
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neurocytoma found that this group exhibited a decline in memory ability and abstract 
thinking, and developed symptoms of anxiety and depression within a 5-year follow-up 
period (Shi et al., 2011). Similarly, Maddrey et al. found that AYA medulloblastoma 
survivors have difficulty with attention, memory, executive function, language, motor 
function, and visual-spatial abilities, and that these deficits are associated with exposure 
to craniospinal radiation at an early age (Maddrey et al., 2005). 
CNS tumor survivors are also at risk for sensory deficits such as visual and 
auditory impairments (Ellenberg et al., 2009; Mostow et al., 2010). Medulloblastoma 
survivors, for example, often experience hearing loss after chemotherapy and radiation 
therapy due to subsequent damage to their cochlea (Moeller et al., 2011 ). 
Additionally, infertility and reproductive health problems are prevalent amongst 
CNS tumor survivors. Males who receive chemotherapy in childhood may develop 
oligospermia or azospermia, while females may experience premature ovarian failure 
(Bleyer, 2007). Additionally, spinal radiotherapy has a dose-dependent risk for damage to 
the gonads that varies by age at treatment and sex of the patient (Goodwin et al., 2009). 
Approximately 30% of women who received spinal irradiation in cumulative doses of>4 
Gy develop infertility (Goodwin et al., 2009). Locating the ovaries prior to treatment and 
varying the path of radiation beam entry, however, can help reduce the total dose of 
radiation absorbed by normal ovaries during spinal irradiation (Harden et al., 2003). 
Fertility may also be affected by cranial irradiation and subsequent damage to the 
hypothalamic-pituitary axis. Hall et al. found that 78% of female brain tumor survivors 
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experience amenorrhea after cranial irradiation, presumably because of abnormal 
production and regulation of gonadotropic hormones (Hall et al., 1994). 
Health-Related Quality of Life for Adolescent and Young Adult Survivors 
Medical advances have dramatically improved the survival and quality of life of 
people who have had acute illnesses or live with chronic disease. Along with that change 
has come a shift in focus towards how disease and illness affect a person's well-being 
long-term, even after curative therapy, as symptoms related to treatment and chronic 
disease may remain. Health-related quality of life (HRQoL) measurement is one means to 
longitudinally evaluate a patient's overall health. The concept ofHRQoL, as defined by 
the World Health Organization, encompasses the physical, psychological, and social 
functioning of an individual, and considers how these factors collectively affect a 
person's overall quality of life (World Health Organization, 1948). HRQoL is typically 
measured through qualitative instruments that are completed by the patient or by proxy. 
In this manner, HRQoL also represents an individual's self-perception of function in 
relation to their disease symptoms and experience. HRQoL distinguishes itself from 
clinical metrics ofhealth because of its subjective nature and its ability to capture the 
more intangible effects of illness. 
In recent years there has been a strong push to incorporate HRQoL into cancer 
care. Cancer and its therapies have the potential to affect the physical, social, and 
psychological function of a patient. As a result, some have argued that the ultimate goal 
of treatment should be not only survival, but also high quality of life (Frost & Sloan, 
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2002; Roila & Cortesi, 2001). In addition, incorporation ofHRQoL and other qualitative 
tools into clinical care can improve patient-provider communication and enhance clinical 
decision-making (Katz et al., 2007). This occurs because HRQoL helps provide clinicians 
with a comprehensive view of the patient overall health and elucidates a patient's needs 
and concerns. This information is known to enable discussions during face-to-face 
interaction (Mullen et al., 2004). 
For survivors, HRQoL can play a crucial role in tracking the progress of patients 
long-term. Disease- and treatment-related symptoms may persist well after curative 
therapy has ended, and it is important to evaluate the impact of these sequelae on survivor 
well-being. Changes in health status may also occur as a result oflate effects from 
cancer, CNS tumors, and therapy. Identifying the impact of these late effects on HRQoL 
provides an additional dimension to understanding the impact of disease and medical 
treatments on an individual and may help inform clinical decisions for future patients. 
The benefits of active HRQoL surveillance for survivors is similar to that for HRQoL in 
cancer patients; providers gain a better perspective of the survivor's overall health and 
well-being and become more aware of the survivor's emotional and social needs 
(Heimans & Taphoom, 2002). Tracking HRQoL among survivors provides an invaluable 
perspective of long-term health after a health event, and provides a more comprehensive 
understanding of the relationship between disease-specific experiences and quality of life. 
Within the adolescent and young adult population, HRQoL measurement needs to 
consider the complex physical, developmental, and social changes that accompany the 
shift from childhood to adulthood and how those transitions may be affected by disease, 
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treatment, and survivorship. A Y As, for example, are at a pivotal point in their growth 
when they are beginning to exert their independence from parents and family. Many 
A Y A patients and survivors, however, have health problems that require them to rely on 
others for help and social support. This phenomenon may be perceived to directly 
challenge the progression of their life, and leads to a diminished HRQoL as a result. 
Adult survivors of childhood cancer, for example, have 3.7 times the odds of being 
unemployed as sibling controls, with the odds being highest for survivors of pediatric 
CNS tumors who received 2': 30 Gy of cranial radiation therapy (Pang et al., 2008). Being 
unemployed can hinder professional development and career plans, limit annual income, 
and ultimately have a negative effect on an individual's independence and HRQoL. 
Within the context of social support, it may be difficult for survivors to convey 
their disease experience to others and relate to peers who have never been or known 
someone who was critically ill. Adolescent patients who recently completed treatment, 
for example, reported apprehension about returning to school and not being able to relate 
to their peers because of their illness experience and its accompanying emotions (Duffey-
Lind, et al., 2006). The stigma attached to having a cancer diagnosis may influence 
survivors' social interactions and the perceived social support that survivors receive in 
school, at work, and from significant others. 
The late effects, adverse behavioral and emotional outcomes, and neurocognitive 
deficits that A Y A survivors of CNS tumors can develop may individually or collectively 
lead to issues related to employment, health insurance coverage, dating, family planning, 
and education. Maddrey et al., for example, found that survivors face psychosocial 
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difficulties with employment, driving an automobile, participation in mainstream 
education, living independently, and dating (Maddrey et al., 2005). 
In addition to the psychosocial and neurocognitive effects of disease, A Y A 
survivors face a potential gap in health care as they switch from pediatric to adult 
providers. From the view of the survivor, changing medical providers can be 
disconcerting because of the strong relationships that they have developed with their 
pediatric clinicians during their illness. Many A Y As report that they do not believe their 
adult primary care physician is knowledgeable enough about pediatric cancer to deliver 
adequate and appropriate care. A qualitative study by Duffey-Lind et al. quoted one AY A 
survivor in their report stating, "Too many times I have sat down with the doctor after 
being treated and felt like I've known more than he has" (Duffey-Lind et al., 2006). 
Hampton echoed this concern when she quoted Dr. Archie Bleyer as saying "young 
adults with cancer are an 'orphan' group" because of medical training's focus on how to 
care for older adults or for young children (Hampton, 2005). This tendency creates a gap 
in knowledge about the provision of medical care to people ages 15 to 40 years. The 
pathology and presentation of disease may be different in the A Y A population, and 
physicians may be inadequately prepared to care for A Y A survivors who are vulnerable 
to adverse late effects of their childhood illness. Childhood cancer survivors also have 
difficulty obtaining health insurance coverage, with 29% reporting problems compared to 
3% of sibling controls (Park et al., 2005). Park et al. found that the risk for difficulty is 
increased for survivors who were diagnosed at age 0 to 4 years, were an A Y A between 
the ages of 22 to 24 years, or had a history of cranial radiation therapy (Park et al., 2005). 
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Collectively, A Y A survivors of cancer may not be receiving adequate health care follow-
up despite their vulnerability to adverse late effects at this stage in their life. 
Survivors of childhood CNS tumor are likely at increased risk for experiencing 
severe treatment and disease sequelae due to the need to treat them with craniospinal 
therapy and chemotherapy at an early age. Among child and adolescent survivors of 
childhood cancer, HRQoL in the domains of physical and psychosocial functioning is 
lowest for people who received cranial radiation therapy and for survivors of CNS 
tumors, lymphoma, and leukemia (Speechley et al., 2006). Similarly, a Canadian study of 
1,334 A Y A and adult survivors of childhood cancer showed that only CNS tumor 
survivors reported poorer quality oflife (QOL) in the domain of physical health, role 
limitations related to poor physical functioning, and poorer QOL psychosocially 
compared to healthy controls (Maunsell, 2006). CNS tumor survivors are also more likely 
to report lower social, emotional, and school functioning compared to survivors of non-
Hodgkin and Hodgkin lymphoma, with school functioning being decreased among 
survivors who received radiotherapy (Yagc-Ki.ipeli et al., 2012). 
Since survivors of malignant CNS tumors are more likely to report medical 
complications, hearing deficits, paralysis, and cerebrovascular incidents than sibling 
controls (Ellenberg et al., 2009), they are more likely to experience role limitations due to 
poor physical health (Maunsell et al., 2006). The neurocognitive and physical sequelae of 
CNS tumors and treatment also make survivors of CNS tumors less likely to leave home 
and live independently during young adulthood than survivors of other malignancies and 
healthy controls (Koch et al., 2006). Overall, CNS tumor survivors may experience 
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adverse social outcomes because of the adverse outcomes and late effects of their disease, 
which is exhibited by their increased risk for lower educational attainment, lower 
household income, lower rates of full-time employment, and lower rates of marriage 
compared to healthy individuals (Ellenberg et al., 2009; Mostow et al., 2010). 
Although several models of HRQoL exist, our conceptualization of HRQoL is 
specific to A Y A CNS tumor survivors. What primarily separates our model from other 
general and cancer-specific models is its inclusion of neurocognitive functioning and its 
implications on social well-being. The model includes the domains of social health and 
well-being, physical health and well-being, mental and emotional health, cognitive 
functioning, health behavior, sexual and reproductive health and well-being, and social 
support systems, and can be seen in Figure 2. 
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Figure 2 Conceptual model of health-related quality of life 
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Evaluating Health-Related Quality of Life in CNS Tumor Survivors 
Generic HRQoL instruments have difficulty capturing the unique experiences of 
CNS tumor survivor and other disease-specific groups. Although using a generic 
instrument allows for comparison across multiple patient and survivor groups, it is 
important to have a tool that is sensitive to the concerns and late effects that individuals 
experience specific to their illness. Avis et al. identified five cancer specific domains and 
seven generic QOL domains that can be used to assess issues that adult cancer survivors 
experience long-term. Cancer-specific domains include physical appearance, financial 
difficulties, distress over disease recurrence, family-related stress, and the benefits of 
cancer. General QOL domains included negative feelings, positive feelings, cognitive 
deficits, sexual problems, pain, fatigue, and social avoidance (Avis et al., 2005). 
Developing a HRQoL instrument specifically for survivors of pediatric CNS 
tumors presents several challenges because of the neurocognitive impairments that are 
prevalent among this population. Self-reporting relies on patient/survivor completion of 
the tool, which may be difficult because of cognitive deficits that affect writing, reading, 
communication, and comprehension. Additionally, there is a wide range of health 
outcomes and morbidities among the A Y A CNS tumor survivor population because of 
the variation in tumor type, age at diagnosis, and age at treatment (Tao, 2005). As a 
result, it is difficult to design a HRQoL instrument that can both capture the breadth of 
functional outcomes and discriminate the subtle differences of experience within this 
group. 
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For our study we sought to identify a comprehensive set of domains for inclusion 
in our final instrument through discussions with survivors and experts, literature reviews, 
and examination of existing HRQoL instruments. 
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SPECIFIC AIMS 
This paper discusses adolescent and young adult survivors of childhood and young adult 
CNS tumors, and presents a preliminary instrument to evaluate health-related quality of 
life (HRQoL) in this population. Specifically, we will: 
1. Present current knowledge about HRQoL in CNS tumor survivors and their 
unique needs compared to survivors of cancer and other benign tumors. 
2. Review existing qualitative instruments that are used to evaluate HRQoL in 
patients with malignant and benign CNS tumors. 
3. Analyze qualitative results from our focus groups with adolescent and young 
adult survivors of CNS tumors. 
4. Explain the development and functionality of the HRQoL instrument that we 
designed for adolescent and young adult survivors of CNS tumors. 
5. Present the HRQoL instrument. 
6. Identify challenges encountered during the instrument's design process. 
We expect this study will: 
1. Emphasize the complexity of the adolescent and young adult survivor experience 
and the need to evaluate their quality oflife. 
2. Provide a qualitative instrument specifically designed for adolescent and young 
adult survivors of CNS tumors. 
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METHODS 
Study Design and Participants 
Recruitment of participants for the study's focus groups, cognitive testing, and 
pilot testing began with identification of CNS survivors through the electronic medical 
records system maintained by Massachusetts General Hospital in Boston, Massachusetts. 
Only patient records from pediatric, family medicine, internal medicine, hematology, 
oncology, and radiology practices were searched. Individuals were eligible to participate 
if they had a diagnosis of a CNS tumor from 2000 to 2010 as established through ICD-9 
codes and were 1 to 10 years post-treatment as established by last known treatment of 
radiation therapy, chemotherapy, or surgery. Individuals also had to be age 15 to 39 years 
at the time of diagnosis, age 16 to 50 years at the time of sample selection, and fluent in 
English. Through this search process we identified 340 potential participants. Each 
patient's primary treating oncologist was subsequently contacted to confirm the diagnosis 
and appropriateness of the patient's participation in the study. If the oncologist 
determined that the patient's participation was appropriate, a recruitment letter co-signed 
by the oncologist was mailed to the patient. The letter indicated that they would be 
contacted and asked to participate in a focus group unless they contacted the study 
investigators and declined to participate. A total of 89 letters were mailed. A member of 
the research team subsequently contacted individuals by phone to inquire about their 
willingness to participate. 29 survivors agreed to participate in the study, 15 declined 
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participation, and 45 did not respond. A flow chart of the sampling procedure is provided 
in Figure 3. 
Total potentially 
eligible 
n=340 
Conf irmation of diagnosis and 1 
appropriateness of participation 
Received 
recruitment letter 
n=89 
I 
1 
Participation determined to be 
not appropriate 
n=251 
ennrocted by phone l1-l ----------,1,---------.1 
Agreed to participate 
n=29 
I 
No response 
n=45 
Declined to participate 
n=15 
A>Signed to focu• group lf-------------------.,1 
Participated in focus groups 
n=19 
Figure 3 Flow chart of study sample selection 
Unable to participate due to scheduling 
n=10 
A total of 19 CNS tumor survivors participated. Among participants, age at 
diagnosis ranged from age 17 to 38 years and age at the time of study selection ranged 
from 24-40 years. Selected characteristics of the participants can be seen in Table 2. 
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Table 2 Characteristics of study participants 
Years 
Age at Age at Years since since 
Sex diag_nosis studJ!.. CNS tumor diag_nosis M alig_nanCJ!.. Tfi!..e o[treatment diag_nosis treatment 
Male 23 25 Adenoma Malignant Chemotherapy 5 Unknown 
Female 36 39 Meningioma Benign Radiation 3 3 
Female 31 40 Glioma Benign Surgery 9 9 
Female 31 37 Acoustic Neuroma Benign Surgery 6 6 
Female 17 27 Pineocytoma Benign Surgery 9 9 
Female 19 25 Choroid plexus papilloma Benign Surgery 6 6 
Male 30 39 Glioma Malignant Surgery 8 8 
Male 26 34 Schwannoma Benign Surgery 7 7 \;J 
+:> 
Male 26 30 Astrocytoma Malignant Surgery 5 5 
Male 28 32 Acoustic Neuroma Benign Surgery 3 3 
Female 32 39 Anaplastic Astrocytoma Benign Surgery; Radiation 7 2 
Female 23 29 Melanoma Malignant Surgery; Radiation 6 6 
Female 25 29 Medulloblastoma Malignant Surgery; Radiation 4 4 
Male 22 32 Germinoma Benign Surgery; Radiation 10 10 
Male 22 24 Temporal Astrocytoma Malignant Surgery; Radiation 2 2 
Surgery; Radiation; 
Female 27 34 Glioma Malignant Chemotherapy 7 5 
Surgery; Radiation; 
Female 32 35 Anaplastic Astrocytoma Malignant Chemotherapy 2 2 
Surgery; Radiation; 
Male 22 25 Anaplastic Astrocytoma Malignant Chemotherapy 3 
Surgery; 
Female 38 40 Meningioma Benign Chemotherapy 3 2 
The research team was comprised of investigators from the Center for Child & 
Adolescent Health Research and Policy at MassGeneral Hospital for Children. The study 
protocol was approved by the Institutional Review Board at Massachusetts General 
Hospital. 
Focus groups 
Five focus groups were conducted at Massachusetts General Hospital in 
November and December of2010. The focus groups lasted an average of90-minutes and 
included three to six participants. Written consent was obtained on the day of the focus 
group. Subjects received $50.00 in remuneration for their participation. All focus groups 
were audio recorded and transcribed. 
The aim of the focus groups was to identify domains and items relevant for 
inclusion in the A Y A survivor HRQoL instrument. Development of the focus group 
guide consisted of a review of existing literature and HRQoL tools in order to compile a 
list of HRQoL domains and sub-domains for the focus group discussions. The focus 
group guide is provided in Appendix A. Each focus group began with a structured 
introduction that informed participants about the objectives of the study and provided 
ground rules for the discussion. Facilitators subsequently asked participants to discuss 
their current quality of life with respect to their CNS tumor and medical treatment. 
Probing during this initial open discussion was non-specific to a particular domain of 
interest. Once participants voiced all of their ideas, the facilitators brought up specific 
domains of interest and asked group participants to comment on their relevance and 
whether they should be included in a HRQoL instrument for CNS tumor survivors. 
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Focus group transcripts were coded independently by two members of the 
research team using the qualitative analysis software NVivo 8.0 (QSR International, 
Doncaster, Victoria, Australia). The initial coding scheme included 1) new domains of 
HRQoL, 2) specific items within the new domains, and 3) any indication for consensus 
affirming or rejecting the domain/item as important. The subsequent coding included sub-
domains for the following major domains: 1) social functioning, 2) physical functioning, 
3) emotional functioning and mental health, 4) school and work functioning, 5) cognitive 
functioning, 6) sexual and reproductive functioning, 7) general impact on functioning, 8) 
health behaviors, and 9) support systems. This detailed coding scheme is provided in 
Appendix B. 
Review of HRQoL Instruments 
Existing HRQoL instruments were obtained through the Patient-Reported 
Outcome and Quality of Life Instruments Database (PROQOLID), which is accessible 
online at http://www.proqolid.org. Instruments were considered if they were listed as 
"HRQL," "Signs and symptoms," or "Psychological function" under the Type of 
Instrument category; were listed as "Generic," "Neoplasm," "Nervous system diseases", 
"Pathological conditions signs and symptoms," or "Psychiatry/Psychology" under the 
Pathology category; or were listed as "Generic for neoplasm," "All," "Fatigue," "Body 
Image," or "Pain" under the Disease category. A total of39 instruments were yielded 
from this search. Only 19 instruments were retained for detailed review. Instruments were 
eliminated from the analysis if: 1) a copy of the complete instrument was unavailable, 2) 
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the items listed were not relevant to A Y A survivors of CNS tumors, 3) the instrument 
was not available in English. Additionally, if several versions of an instrument existed by 
age group or condition, only the version for the A Y A population and/or CNS tumor 
diagnosis was included in the analysis. The items within each instrument were sorted 
according to the domains and sub-domains listed in our Detailed Coding Scheme and by 
additional instrument-specific domains found in the literature. 
Using the focus groups and existing HRQoL instruments, the study team 
generated a set of 324 items for potential inclusion in the QUEST CNS instrument. All 
items were written at a middle school reading level and phrased for use with a Likert 
scale. 
Expert Panel Process 
A panel of 11 experts in the clinical care of people with CNS tumors and in 
HRQoL measurement was assembled for this study. The experts included pediatric 
hematologists/oncologists, oncology nurses, and psychologists. The panel provided 
prompt feedback for the study protocol and evaluated the effectiveness and 
appropriateness of the items in the QUEST CNS instrument throughout its development. 
Members of the expert panel included: Peter Manley (Pediatric Neuro-oncologist at 
Dana-Farber Cancer Institute), Karen Loechner (Pediatric Endocrinologist at Dartmouth-
Hitchcock Children's Hospital at Dartmouth), Annah Abrams (Pediatric 
Hematologist/Oncologist at Massachusetts General Hospital), Mary Jo Gonzales (Nurse 
Practitioner at Massachusetts General Hospital), Christine Trask (Child Clinical 
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Psychologist at Rhode Island Hospital), Nina Kadan-Lottick (Pediatric 
Hematologist/Oncologist at Yale School of Medicine), Cori Liptak (Pediatric 
Psychologist at Dana-Farber Cancer Institute), Jill Brace O'Neill (Pediatric Nurse 
Practitioner at Dana-Farber Cancer Institute), Lisa Kenney (Pediatric 
Hematologist/Oncologist at Dana-Farber Cancer Institute), Elyse Park (Psychologist at 
Massachusetts General Hospital), and Sara Chaffee (Pediatric Oncologist at Dartmouth-
Hitchcock Medical Center). 
After generation of all potential QUEST CNS items, the questions were arranged 
in an electronic spreadsheet and distributed to the expert panel for evaluation. Experts 
were asked to rate each item for content validity. Ofthe 11 experts, 8 sets of ratings were 
returned. All returned ratings were summarized as Content Validity Ratios (CVR), which 
is a statistical measure of consensus developed by Lawshe (Lawshe, 1975). CVR = (ne-
N/2)/(N/2), where "ne" equals the number of subject matter experts who indicated that the 
item as essential and "N" equals the total number of subject matter experts rating the 
item. The CVR equation produces outcome values that range between -1.00 and + 1.00, 
where a CVR of 0.00 indicates that 50% of the panel believes the item to be essential. 
Lawshe established the CVR and determined minimum CVRs for different panel sizes 
based on a one-tailed test at the a= 0.05 significance. For this portion of the study, we 
received 8 ratings from our expert panel, which requires items to have a CVR of 0. 7 5 in 
order to meet a 0.05 significance level. Only items that had a CVR equal to or in excess 
of0.75 were retained for future consideration in developing the QUEST CNS instrument. 
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RESULTS 
Focus Group Findings 
The fmdings from our focus groups identified several major domains of HRQoL 
for our participants. These domains are: 1) Physical Health and Well-Being, 2) Cognitive 
Functioning, 3) Mental Health and Well-Being, 4) Social Well-Being, 5) Reproduction 
and Sexual Health, and 6) Support Systems. Below are select examples of experience by 
major domain. 
Physical Health and Well-Being 
Physical health problems in our focus group population were largely related to 
seizures, headaches, pain, fine motor deficits, balance and coordination problems, 
sensory deficits, sleep problems, and fatigue. Some of these symptoms were inter-related, 
such as decreased vigor due to anti-seizure medication. Below is a more in-depth 
exploration ofthe sub-domains of physical health. 
Sensory Deficits 
Vision and hearing impairments were reported by several focus group 
participants. Most of the sensory deficits had improved over time since they arose and all 
deficits were either a symptom of the CNS tumor or a side effect of treatment. Reports 
from participants indicated that the severity and impact of sensory impairments on quality 
of life was quite variable. In addition, participants reported feelings of frustration and 
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anxiety associated with tasks or situations that were difficult because of their sensory 
impairment. One participant, for example, noted that: 
"I feel a little bit more anxious because of my vision problem. So as a 
direct cause, I definitely get more anxious when I'm walking in a crowd. 
I've mentioned at the mall, sometimes my wife isn't there and I don't like 
tripping over children. I don't like bumping into things. Sometimes I'll 
walk into a wall with my shoulder and get really mad at that. Like just, 
'Ugh!' But I can't say that there's anything that, other than the vision the 
indirect effects, that's caused any emotional problem.[ ... ] I don't think 
that I am any more anxious as a person, as a personality because of it. It 's 
just that there's this factor, there's this cause right." 
Those with vision problems reported difficulty driving, seeing in the dark, focusing on a 
single object, and walking in public places or areas that they were not familiar with. 
Individuals who had difficulties with only one of their eyes also reported the onset of 
headache or pain because of the imbalanced sensory input from their eyes. Those with 
hearing problems had difficulty being in a room with multiple people, determining the 
direction and source of a noise, and frequently had problems with balance. 
To cope with the sensory deficits, participants relied on peer or familial support, 
depending on what setting they were in. At work, most people reported that their 
colleagues understood their needs and were accommodating. At home, participants relied 
on their spouse/partner, children, and other family members to help them. The majority of 
our participants, however, had adjusted to their sensory deficit well, and did not require 
any assistance from others. In addition to relying on others for help, participants managed 
their condition by avoiding activities known to trigger the symptoms of headache, pain, 
and loss of balance that are associated with their sensory deficit(s). 
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Deficits in Fine Motor Functioning, Balance, and Coordination 
Difficulties with balance, coordination, and fine motor skills were prevalent 
among participants who had radiation therapy or suffered from late effect stroke. 
Participants reported that they received rehabilitation therapy after the onset of these 
deficits, and had since adapted to them. One participant explained: 
"I'm left handed so the, my left side doesn't do sometimes what I want it 
to. And then after the radiation I had a small stroke a couple of months 
later. Longer than a couple of months later, maybe 14 months later. So 
that ' s also affected. When I go to the gym the treadmill, I have to hold on 
for dear life or 1.. .I have no balance. [ ... ] But other than that, my right side 
works fine. I've definitely adjusted to those things." 
Among our focus group participants, no one had limited independence due to a physical 
disability and all participants reported that they could complete activities of daily living 
(ADLs) on their own. Motor deficits, however, required some participants to alter their 
career path in order to accommodate their new level of physical functioning. One person, 
for example, left the medical field because she no longer had the manual dexterity to 
perform procedures on patients. Similarly, some people had to restrict their physical 
activities, such as dancing and sports. One person who reflected on this type of activity 
restriction stated: 
"Well I used to go dancing every night. And I did this kind of dancing 
where you do lots of twirling around. Well, swing dancing and lots of 
conja dancing where you 're getting spun from one person to the other 
person. Well, I couldn't really spin. But also, it's a little disorienting and 
you know how when you spin you track when you 're dancing. You can 
just track a spot. But that's, I mean, I'm sort of getting better but now I 
just don't really go. But for me, that was my big social thing was dancing. 
And it was a big physical thing. And after the surgery, I went a little bit 
and now I don' t go." 
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Although dancing was not a vital activity for independent living, the participant 
expressed a loss of social interaction as a result of her inability to dance. Thus, it is 
important to consider the social implications of decreased physical health and subsequent 
activity restriction. Although balance, coordination, and fine motor impairments can 
significantly affect an individual's professional and social life, they did not seem to 
directly hinder a person's independence and ability to perform instrumental ADLs 
(IADLs) or ADLs within our study sample. 
Fatigue and Lack of Energy 
Fatigue and decreased energy was widely reported among focus group 
participants. People reported having to take naps regularly, having a lower baseline 
energy level than prior to their tumor, not being able to stay up late and participate in 
evening social activities, and having difficulty keeping up with their children. For some 
people the fatigue was severe enough to affect their quality of life. One participant stated: 
Do I get depressed? Absolutely. Do I get tired? I still get really tired. I 
used to be go, go, go all the time and I just physically can't do it anymore. 
I can' t. I find myself having to take naps in the afternoon. And that's part 
ofwhere some of the depression comes in. You're so active and then you 
come home from work and you have to lay down and take a nap for an 
hour before you can function again. And it's hard to explain to people, 
unless they've lived through it they just don't get it. 
Although this participant is able to physically cope with their fatigue by taking naps, it 
appears that living with chronic fatigue has led to a decreased energy level overall and 
feelings of depression. The participant no longer feels that they can function at their pre-
tumor baseline, and this has resulted in a decreased quality of life emotionaLly, socially, 
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and physically. Other participants expressed similar feelings of depression and 
conflicting identities with regard to their activity levels prior to and after their tumor 
diagnosis. 
Medication and Side Effects 
The use of anti-seizure medication and pain relievers to manage residual disease 
symptoms was identified as a source of frustration because of the side effects of these 
medications. Several participants expressed their desire to stop or change their anti-
seizure medication because of fatigue, poor quality sleep, and changes in mood. One 
participant, for example, described the lengthy process of stopping her medication: 
"I think I wasn't metabolizing the meds very well, maybe because I 
reached some sort of toxic level and they wanted to just keep me there. 
And I tried to cut back on them. But we had a lot of discussion about 
whether it was safe for me to have less meds because of the seizures. But I 
just couldn't function like that so I took myself, well, we did it together, 
but I took myself off after a year because originally, they said, 'You'll be 
on for a year.' And at a year I said, 'I'm ready, let's go.' And he said, 
'Well, you should really be on for three years.' And I was like, 'No! I 
cannot stay on these things.'" 
The decision to remain on medication can be a delicate one. The side effects of 
medication can be severe and significantly decrease HRQoL in survivors. During changes 
in anti-seizure medication dosing or brand, participants recalled an increased severity in 
side effects that affected their quality of life. Since seizures and migraines are symptoms 
that many CNS tumor survivors continue to manage, it is important to consider the 
impact of these medications on overall quality of life in the long-term. 
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Collectively, the physical health of some of our participants limited their full 
participation in athletic and social activities. Determining whether an activity is 
physically feasible has become a regular consideration for some survivors, and their 
inability to participate fully in activities that they used to engage in can be disappointing. 
One participant said, "I'm not sure ifl have as much real fun like I. . .I mean, there is a 
part of me that is like, 'Okay, can you do this? Let's make sure that you can do this.' The 
physical part of it." As seen throughout our focus group discussions, CNS tumor 
survivors have to cope with their new baseline level of physical functioning. Tumor and 
treatment sequelae have resulted in lingering disease symptoms such as seizures, pain, 
fatigue, motor deficits, and sensory deficits. The management of those conditions and 
their chronic nature introduces an additional dimension to their daily lives, as they must 
cope with these physical issues and any related consequences of their decreased function 
when engaging in their professional life, family roles, and social activities. Additionally, 
it is important to consider the adjustment to a new level of physical functioning since the 
emotional aspects of this transition and living with chronic health conditions may persist. 
Cognitive Functioning 
Nearly all focus group participants continue to experience cognitive side effects 
related to their CNS tumor and treatment. The most common residual cognitive deficits 
reported were in the areas of short-term memory, visual-spatial tasks, learning, 
reading/writing, attention/concentration, and speech/language. The severity of the 
cognitive deficits was highly variable. Some ofthe focus group participants reported that 
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they cope easily through the use of organizational habits, while others reported that they 
have difficulty completing tasks at work or school because of their cognitive symptoms. 
One person explained: 
"I am also in the middle of a doctorate. I was supposed to take my exams a 
year ago. I was supposed to take them in the spring. I was supposed to 
take them this fall. And I just keep putting it off because my ability to 
study and retain all that I have to take for those qualifying exams is 
overwhelming to me. So I have big worries about whether I'm going to be 
able to finish, because this happened in the middle of this. I'm just, it's 
like the jury is out still on this subject. I'm just not sure ifl'm going to 
recover from this brain fog or what it's about. I don't know." 
This participant's memory problems have disrupted the progression of her education, 
which raises uncertainty and anxiety about her future in that professional path. These 
sentiments were shared by other participants who were in similar situations. 
The cognitive deficits also had the potential to affect instrumental ADLs. Many 
participants reported that everyday tasks such as driving home and taking medications 
were difficult because of memory deficits, visual-spatial deficits, and problems with 
writing and language. One participant, for example, recalled how hard it is to write a 
check: 
"I remember trying to write a check, like a rent check and my eyes hurt 
and I signed half of my first name and took a break and then came back 
and signed the rest of it. And I wrote my middle initial and took a break. 
You know and then ten minutes later I wrote my last name." 
In another focus group, several participants mentioned "getting lost" as a regular 
occurrence because they could not geographically identify where they were or how to get 
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from one place to another while driving, even if it was a familiar route such as traveling 
home. 
It is clear from our focus groups that many A Y A survivors of CNS tumors 
continue to experience cognitive difficulties. Although most of the participants coped 
well by changing their organizational habits, cognitive deficits have the potential to 
negatively affect quality of life through their impact on an individual's professional life 
and instrumental ADLs. It is also important to recognize the emotional aspects of living 
with cognitive deficits, which can include anxiety, frustration, and feelings ofuncertainty 
about the future. 
Mental Health and Well-Being 
Feelings of depression, anxiety, frustration, and uncertainty about the future were 
prevalent amongst survivors in our study sample. These sentiments centered largely 
around the HRQoL changes that the participants had experienced since completion of 
their treatment, and were related to the impact of their CNS tumor on their professional 
and personal lives, changes in their personal outlook, existential issues, and their 
transition into survivorship. On the whole our participants have coped well mental health-
wise, but it is clear that certain on-going HRQoL issues evoke emotional reactions. As 
one participant explained: 
I did have the depression, I do get frustrated with the memory loss and the 
fact that I can't do physically as much as I used to do. But I've been able 
to work around it. You just deal. There is always another way around 
something, so if you have to take that nap, well, guess what? Thankfully, 
the way that my work schedule is, my wife and I are lucky enough, we 
have a two-family home and my mother and father-in-law live on one side 
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and we live on the other. And my mother-in-law is recently retired, so she 
watches my son. So I'll get home from work, pick him up and he'll finish 
his milk for that period and thankfully, usually, we can get him to take a 
nap. Well, guess what, he naps. If we put him in the crib, he ' s going to 
wake up. So we kind of chill out on the couch and usually nod off 
together. So that's helped a lot. You know, defmitely you just work 
around it. 
This survivor's adjustment to living with memory deficits and physical health problems is 
representative of many of the experiences that our participants reported for coping with 
their chronic conditions. Although the survivor has adjusted well, he remains frustrated at 
times with how his health issues affect his daily routine and lifestyle. Some participants 
in our focus group reported more intense feelings of frustration and sadness. One 
participant, for example, stated: 
Well, I can't see. Every time I walk into, I walk into parking meters all the 
time. The one person that I'm walking with, they know, but all the people 
around you, they start laughing. I'm a pretty strong person, but when I hit 
a telephone pole, it can be such a little thing but it just resets everything. 
The fury and the sadness and all ofthe emotions that just for a moment, it 
makes you really think, "nobody else walks into poles. Why do I have to 
walk into poles?'' 
The differences between these two accounts highlight the heterogeneous emotional 
consequences of living with a chronic condition and the transition into survivorship. It is 
important to consider the variability and complexity of emotional well-being when 
developing an HRQoL assessment tool, as the instrument should be sensitive to these 
subtle differences. 
In addition to frustration, feelings of uncertainty about the future were expressed 
by several participants. When discussing her career, one participant stated: 
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No, I want to work, but now six years of being at home, my degree is kind 
of fading away there. We were waiting for this summer was my five year 
mark of being off of chemo, so we were kind of using that as a marker. 
And we just surpassed that and got my daughter through kindergarten and 
my town only has half-day kindergarten so that was working out together. 
And now I'm using this here to reassess what I'm capable of doing now, 
what I can do, what I want to do. It changes your entire life. I'm not the 
same person that I was six years ago when this happened. 
Having a CNS tumor led to significant life changes for this survivor, and led her to 
decide to be a stay-at-home mother instead of returning to work. In this instance, the 
participant expressed uncertainty about her future career, and expressed that her current 
role as a full-time mother is in conflict with her desire to work. It is important to note the 
coincidence of her diagnosis with the birth of her daughter, as that occurrence may be 
specific to the A Y A population since young adulthood is inclusive of the most 
procreative years. It is also important to recognize how the CNS tumor experience and 
age at diagnosis impact's a person's identity and self-perception. During a discussion 
about the tumor experience one participant noted that: 
"[ ... ] it's like some people base their lives on roles that they have to 
certain people, and that was a big role change because I wasn't the most 
helpful person anymore. I felt like I was the most helpless. [ ... ]How about 
now? Now I feel like I'm helpful, but I'm a very cautious helper." 
Another participant echoed, "I know that I don't feel that different. So when I look 
around and see that I am different, the dissonance between what I think and what I see, 
that's what hurts." For both of these participants, the tumor experience has led them to 
redefine their social roles and challenged their self-perception. Such identity conflicts and 
feelings of helplessness were pervasive throughout the focus groups. It is unclear how 
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they have affected mental well-being, but the prevalence of these sentiments is notable. 
In general, feelings of helplessness were frequently accompanied by thoughts about self-
worth. One participant stated: 
"[ .. . ] sometimes you feel like your value to your family or society is not 
as good as the person next to you. I feel like, wow, I'm sitting back, I'm 
not making my contribution to society by going and there and working. 
[ .. . ] You feel like you are less of a person because you can't go out there 
and say, 'I'm going to get my keys and go to work and do this' and you 
see other people with disabilities, and sometimes even worse than yours 
out there working, and it's like, 'Wow, why can't I do that?' You know?" 
This statement demonstrates how decreased functioning can lead to a perceived decrease 
in self-esteem as a result of their inability to fulfill social roles both professionally and 
personally. In conjunction with self-esteem issues, body image was a frequent topic of 
discussion. One participant stated: 
"The only thing that I am self-conscious about is the scar. I actually right 
before the surgery I had shaved my head just because. It was a style I 
wanted to try. Now there's no way that I could do that because there's a 
big gaping horseshoe scar in the back of my head. And if I ever lose my 
hair I'm going to feel a little bad about that. So far it hasn' t happened in 
that area so I'm happy." 
Survivors may face emotional issues related to self-esteem and body image that are 
directly related to their CNS tumor. Survivors also mentioned body image and self-
esteem issues when they discussed treatment, which for many participants was the time 
period during which they were in the poorest physical health and most visibly ill. 
Despite the ongoing difficulties of survivorship, our participants expressed quite 
positive or reinvigorated life outlooks as a result of their experience. One participant said, 
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"I'd definitely like to second the fact that I also feel like I dodged a bullet 
because I just got radiation, you know, that's it. Didn't have to do 
anything really debilitating. There's always the thing that you think you 
had it bad and then you find out that it could be so much worse. And you 
should just stop pitying yourself. You know. 
Another participant stated: 
"But everyone tells me, ' Oh you have such a positive outlook on life. Blah 
blah blah.' 'Hey, thank god I haven't been as sick as the two of you, but I 
was really sick for a long time.' Why? I mean, I'm here, I'm able to wake 
up, put my feet on the floor. I have a beautiful son. I'm here. Why? Why 
be miserable? My life is too short to be miserable." 
For both of these participants, surviving a CNS tumor gave them a newfound outlook on 
life. Several participants noted how their perspectives on survival had been affected by 
their treatment experiences, as they came into contact with other patients who were much 
sicker than they were at the time. Although these feelings are largely positive, it is 
important to consider the emotional effects of the tumor experience on life outlook when 
looking at HRQoL. 
Mental health and well-being was largely consistent within our sample 
population. Survivors experienced residual stress and anxiety when managing their 
chronic health conditions and altering their lifestyle to accommodate their decreased 
functioning. Many of these changes included not being able to fully participate in 
activities that they wanted to, and some of our participants expressed frustration and 
reported decreased self-esteem as a result. These comments coincided with reports of 
feeling helpless or disempowered. Additionally, the experience of being diagnosed and 
treated for a CNS tumor seemed to have a long-lasting impact on survivors' life outlook. 
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Social Well-Being 
All survivors in our study sample reported positive and/or negative changes in 
their interpersonal relationships with their peers, friends , significant others, co-workers, 
and family members. Some people discussed difficulties with keeping up with their peers 
and having to set limits on their social activities because of their disease symptoms. 
Others described how difficult it was to relate their tumor experience to peers because 
their peers were healthy and had not dealt with the implications of a life-threatening 
illness. Issues of discrimination and stigma were also prevalent during focus group 
discussions, and each participant had a different strategy for dealing with these issues. 
Some survivors reported that their peer groups changed significantly as a result of their 
CNS tumor. 
Social Activities 
Several participants reported instances when their health impeded their ability to 
fully participate in social activities. One participant stated: 
"I used to out to the club all the time and all of that and then just stopped, 
you know? And I can't say why I stopped,[ ... ] I know I had a lot of and I 
still have some balance issues so the lights and the loud noises and stuff 
really started to affect me and stuff like that. I was getting accused of 
being intoxicated and I don' t drink usually, so I'm like, 'No. I promise, 
see the scar? I promise. ' So that calmed things down." 
In this instance the participant's balance and sensory problems made it difficult for her to 
go out with friends as she had before her tumor. Additionally, the problems were 
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perceived negatively by people she interacted with because they assumed her poor 
balance was due to intoxication. These negative experiences are likely what led her to 
stop going out, which changed the way she socializes with others. Another participant 
described a separate dimension of the effects of health on social activities: 
"I was never the party or hang-out type person, but sometimes I sit with 
my friend and he's watching a movie and I'll listen to it and it's like 
sometimes you feel like, they're enjoying a movie and it's like, 'what's 
going on?!' and they say, 'this happened.' And you feel like you're the 
oddball because of that. Or if you're on medications that make you react 
certain ways.[ ... ] I've learned how to deal with it now, but sometimes 
that' ll put your anger from zero into overdrive over the smallest thing." 
This participant's account demonstrates the emotional implications of the social 
limitations that he experiences while interacting with others. Although he participates in 
activities with friends, he expresses a sense of isolation and frustration because his visual 
impairment prevents him from engaging in the activity in the same manner as his peers. 
Additionally, the side effects of his medication enhance these emotions, and make it 
difficult to control his anger while interacting with peers in these situations. Although 
survivors retained friendships and continued to participate in social activities, the extent 
and mode of their participation was different in comparison to their social activities 
before their tumor. 
Friendships 
Survivors reported varying experiences with friends both during and after their 
treatment. The majority of our participants commented on how difficult it was for them to 
maintain or develop friendships with people who did not know how to deal with their 
tumor experience. One participant stated: 
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"But what sort of happened socially is that people just ignored the whole 
thing and just didn' t talk to me very much and were just going to wait and 
see what happened or they just got super worried. I had two friends who 
were just super well-balanced and were just a wonderful core for me. But 
it's two, you know? Of a huge number and it was hard. And I felt like, 
some people who had known me freaked out [ ... ]" 
Another participant expressed similar concerns: 
"I think some people who haven't...it happened when I was 31 and that 
feels like you' re pretty grown up, but a lot of my friends who were sort of 
in their 30s or late 20s, they just have never had a friend who had a real 
problem I think. People have really been healthy in their lives. I got a lot 
of weird responses and it was really hard." 
The experiences of both participants reflect the difficulties of surviving a life-threatening 
illness at such a young age. The inability of some survivors to maintain all of their 
friendships because of others' reactions to their CNS tumor is an important A Y A-specific 
issue. These social experiences may also influence the way that survivors interact with 
others moving forward. As one participant noted: 
"I am a little more hesitant to just make immediate friends . I used to be a 
very social kind of quick sort of fun, immediate connector. And I don' t 
really do that.[ . .. ] I want really good friends." 
Thus, being an A Y A survivor of a CNS tumor can have a significant impact on 
friendships and the ability to relate to same-age peers. 
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Dating and Intimate Partnerships 
The impact of survivorship on dating and intimate partnerships came up 
frequently within our focus groups. Of the survivors who were in romantic relationships 
prior to their diagnosis, some were still with that person and others reported that their 
diagnosis was the central reason why the relationship ended. Participants who had the 
same partner at the time of the study as they did before their tumor diagnosis reported 
that having a CNS tumor had improved the quality of their relationship. The issues that 
arose within the context of dating, marriage, and intimate relationships were varied, and 
seemed to vary by the strength, duration, and stage of the relationship and the survivor' s 
marital status at the time of diagnosis. 
The most prevalent issues arose during discussions of dating. Some participants 
who were dating at the time of the study reported that it took time for their desire to date 
to increase after completion of treatment. One participant explained: 
"When I was diagnosed in 2003 it was, 'Okay. I'm not going to let 
anybody have a real close relationship with me,' because I had no idea 
what was going to happen. They can't remove it. But I've become more 
optimistic where now I find myself worthy of a relationship. So I really, 
I've opened up the door to a relationship 'cause I had relationships but it 
was basically short term. I'd say, you know, you want something serious 
move on 'cause I can't commit to anything. And I didn't want anybody to 
commit to something ifl wasn' t guaranteeing myselflong term physically 
for them." 
This participant' s experience demonstrates how surviving a life-threatening illness can 
raise concerns about survival and their long-term outlook romantically. Once dating 
begins, however, the focus shifts to how to bring up their tumor experience to their 
significant other. One participant stated that: 
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"[ ... ] it's sort of a sore subject to come up with while you're dating. It's 
not something that I actually wanted to tell my, or anybody I was dating 
seriously. So yeah, it's a little awkward conversation. You don't know 
whether it's genetic or how long you're going to be with that person. If it's 
going to affect their life 50 years down the road. Yeah, it's a sore subject. 
In the end, I mean there hasn't been a single person I've dated that's 
seemed to have been affected by it but, by that conversation everybody 
seems to be very understanding that it was dealt with. It was taken care 
of." 
In both instances, concerns about long-term survival impacted how survivors approached 
dating. Additionally, several of our participants expressed concern about the reaction of 
significant others to their tumor history. No one, however, reported an adverse reaction 
from their date, and many participants considered revealing their experience to be an 
awkward yet benign step while dating. 
Alternatively, some survivors had refrained from dating. One participant, for 
example, stated: 
"I have a friend at work who is [ ... ] like, 'Why do you not have a 
girlfriend?' And I think it's because of the anti-depressants because I just 
don't care. [ ... ]I have thoughts, but I know as a brooding teenager, what I 
was in college and when I drank and went crazy, and what I am now. I've 
calmed down, it's not a priority for me, I'm the priority now. So to take 
that into account, when I think about myself in ten years, that sort of 
scares me, that since I don't have that drive, where am I going to be with 
respect to dating, having a lady-friend, where will I be in ten years when 
I'm 35 and single?'' 
Here, it is unclear whether this survivor's lack of interest in dating is due to his mental 
health or is a consequence of his growth and personal development. Similarly, some 
participants had reservations about dating because their long-term survival is unknown. 
One participant explained: 
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"[ ... ]when I got diagnosed, even now it's like I don' t feel like I deserve to 
be with someone because of my condition. Because it's like, living each 
moment for the fullest and it's like I don't want to get that connection with 
somebody or somebody get connected to me and then something happen 
and they feel like they were cheated. In a way, I feel like I sort of don't 
deserve it." 
Unlike the other survivors whose dating lives were affected by concerns of long-term-
survival, this participant does not feel worthy dating others. Overall, the experiences 
shared by these participants demonstrate how the emotional effects of CNS tumors have 
the potential to impact a survivor's dating life and interpersonal relationships, especially 
as an AYA. 
Family Relationships 
Family relationships were reported to be frequently affected by the CNS tumor 
experience and during survivorship because of the survivor's need to rely on relatives for 
support. In most instances, reliance on family as a support system resulted in more 
intimate family relationships. Additionally, some people reported that thinking about 
their family was inspiring, and helped motivate their recovery and transition to 
survivorship. The most prevalent issues regarding family, however, revolved around 
survivors' relationships with their children. One participant stated: 
"Where my tumor is, or was, there are still residuals there, but one of the 
main side effects was short term memory loss. My daughter just thinks it's 
hysterical. She doesn't get what cancer is yet and she doesn't need to 
know at six. She knows that Mommy had a boo-boo on her head when she 
was growing inside me and stufflike that. But she's like, 'my mother 
never remembers anything!"' 
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Although the effect of CNS tumor survivorship on parenting is a specialized concern 
within the A Y A population, it is an important one. How survivors navigate the issues of 
their tumor experience and survival with their children is potentially challenging, and 
being able to capture this complex process may give a more comprehensive 
understanding of survivor HRQoL. 
Impact on Others 
The impact of survivorship and health on others was noted by several survivors. 
The people mentioned by participants included family members, spouses, and children. 
One participant recounted the effect of his tumor diagnosis on his partner: 
"Well, we were supposed to get married that June. And then I had the 
cancer in March so really, had to postpone the wedding and everything. 
And then I was, no I told her 'Look, we're not married yet. I'm a wreck. 
You don't have to stay with me, really 'cause I don't want your pity, if 
that's what it's going to be,' but there hasn't been that. It's just made 
things stronger. She's still the one that's most worried about me, of 
course. Cause if it happens to you you're just very like 'Meh, whatever.' 
But if anything happens to you, it's the others that have to deal with it." 
This participant's experience demonstrates that the tumor experience extends to those 
closest to the survivor. Although this instance resulted in a positive outcome, it is 
important to consider how the tumor experience impacts others in the survivor's life and 
the relationships that the survivor has with that person. In the quotation that follows, for 
example, a participant details the stress of her tumor on her child: 
"She [daughter] lives in fear. I wasn't able to prepare her. And no matter 
how much I continue to try and work with her[ ... ] I didn't do it well and I 
didn't do it right apparently, because she is still terrified that if Mom 
sleeps beyond what she thinks are normal parameters, I'm going to die and 
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I'm going to leave here. I know that you ladies are talking about having 
babies, which is a wonderful thing but then when you have them and they 
go through it with you, I didn't want any of this for them." 
It is important to note how significantly affected survivors' children were by their 
parent's disease and lingering symptoms. Survivors that voiced this issue expressed 
feelings of guilt and sadness, and it is important to consider the ramifications of long-
term survivorship on parenting and a survivor's emotional well-being. 
Stigma and Discrimination 
Participants had mixed feelings about the stigma of survivorship and chronic 
health problems. Most stated that they were comfortable with these aspects of their 
personal experience and identity, but that they were not always comfortable sharing their 
tumor experience with others due to discrimination or stigmatizing reactions. One 
participant explained: 
"I don't want to hide it. It's been my experience that it's not me that can't 
handle it, it's everyone that I tell. I learned pretty quickly that you have to 
be really careful with this information. [ ... ] People don't want to hire 
somebody who can't remember things or whatever reason, it becomes ... I 
don't want it to be that way and I was originally so open. I was like, 
'Yeah, I got a brain tumor, I can't really see this.' [ ... ] But it is such a 
shock to people." 
The adverse reactions and job discrimination experienced by this survivor are an example 
of how difficult it is for survivors to candidly discuss their health and tumor experience 
with others. In addition to discomfort, stigmatizing attitudes may interfere with a 
survivor's professional growth. Other participants stated that they were careful about who 
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they shared their tumor experience with because of concern for being labeled 
incompetent or being treated differently. One participant recounted a negative 
expenence: 
I come from a small town and pretty much that was the only thing that 
defined me for two or three years, "Oh that's the kid that got brain 
cancer." That was really hard for me because I felt that I was so much 
more than that. I did all of this volunteer work, I traveled, I'm an architect. 
I have all these things about me and every time someone came up to me, 
whether they knew me well or were just meeting me, it was "how are you 
feeling?" and things. And I had a lot of anger, a lot of anger. But I found 
that the best way to combat that was you know, to phrase it in a positive 
way. I make bad cancer jokes, like really bad cancer jokes. You go about 
it and you're like, Yeah, I got a tumor when I was 25 but there are all of 
these, oh it's funny now because I can't walk a straight line. I look like 
I'm drunk all the time. I wear heels but I look like I'm drunk all the time. 
Those kind of jokes and stuff. You phrase it in a positive light. [ ... ] I had a 
few episodes where my bosses thought they were helping me. They'd 
introduce me to the clients, "Oh, [name] just got back from cancer 
recovery." And I just felt that people weren't giving me credit. It's just, 
brain tumors, they just assume you're brain damaged. They'd talk down to 
you and things. That was incredibly insulting. So, I just like to tell people 
on my own grounds after they get to know me and know, that, 'hey, I'm 
normal."' 
Most participants felt uncomfortable with the reactions from others when they mentioned 
their tumor. As seen in the examples above, stigmatization of the survivor is a definite 
possibility, and may result in a biased view of the survivor, discounting of their abilities, 
professional difficulties, and feelings of frustration. It is important to consider the social 
implications of having a chronic condition and being a survivor of a life-threatening 
condition such as a CNS tumor. 
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Relating to Other Patients 
Participants universally felt that they benefited from interactions with other 
patients. They noted that the underlying empathy between survivors of CNS tumors and 
current patients in similar health situations was what enabled them to connect with other 
patients so quickly and well. As one participant noted: 
"One thing that I notice is that there's a lot of people in the last year 
who've had, who told me that they had cancer and when you tell them, 
'Oh me too,' it just puts your conversation in a completely different level. 
Or they think that, or they realize that you really understand. And I'm just 
feeling more and more grateful." 
These types of connections can also be made with family members of patients. One 
participant recounted her relationships with a co-worker who had a daughter with cancer, 
"We wouldn't have been able to talk like that and since we've gone to the Jimmy Fund 
Walks. We go every year together in honor of his daughter so there ' s a little bit of a 
kinship there." Most participants in our focus group noted how important they felt that 
patient support groups were to their ability to cope both during their illness and as a 
survivor. Many of them found solace as a survivor by providing support to current 
patients. The relationships that survivors can have with other survivors and patients are 
an important part of the CNS tumor survivor experience. 
Reproductive and Sexual Health 
Family Planning 
Surviving a life-threatening condition led several participants to question their 
long-term ability to parent. Some participants expressed reservations about having a child 
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because they were uncertain whether there was a genetic component to their CNS tumor 
and did not feel comfortable with the possibility that they would not survive long enough 
to raise their child. One participant recounted a discussion that he had with his doctor 
about having a child: 
"Right, we were having a conversation over coffee one day, I was having 
it with my doctor and we were talking about children. [ . . . ] And I said to 
him, 'What do you think? Honestly, what's your thought process?' [ ... ] 
and he said, 'What's the amount oftime that you would feel comfortable 
being with your child, assuming that you could have a child right now?' 
And I said, 'I don't know. I want them to get to high school at least ... ' 
And he said, 'Do you want the statistical answer or do you want the 
personal answer?' And I didn't want either." 
The concerns about long-term survival and having a family were prevalent among our 
participants who were at that stage in their life. It is important to assess the survivor 
experience within the contexts of being able to have children and having the longevity to 
raise a family. 
Alternatively, other participants reported that their tumor diagnosis invoked an 
urge to have children. One participant, for example, stated: 
"I felt very much like, 'Okay, I need to have a child now.' I think it was 
because I was like, 'I've been with all of these people who are kind of 
close to death and having this process and seeing all of these people 
having so much difficulty and struggle and I just felt like I wanted to 
really have a lot of joy. I might have pursued being a parent a little more 
after having had this surgery, but I was also, I had the surgery when I was 
31, so I really wanted to have a child before I was 35. So I might have 
been pursuing that anyway because of my age. And I did feel like, "this is 
great. It's time! Let's have a child!"' 
As mentioned by the participant, it is likely that her desire to have a child was due to both 
her age and her tumor experience. Overall, the decision and ability to have a child and the 
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emotional issues related to this process are important aspects of survivor HRQoL, 
especially in the A Y A population. 
Libido and Sexual Health 
Issues related to libido and sexual health did not come up often during the focus 
group discussions. The only notable comments from participants surrounded decreased 
libido due to ongoing hormonal issues. Since CNS tumors and their treatment have the 
potential to damage the hypothalamus-pituitary axis and gonads, it is important to capture 
sexual and libido sequelae that survivors may experience. 
Fertility and Pregnancy 
Several participants identified fertility as a component of their quality of life that 
was affected by their tumor. Due to the potentially detrimental side effects of radiation 
therapy and chemotherapy on reproductive capacity, several survivors mentioned the 
consequences of their care decisions on their current desire to have children. One 
participant talked at length with her providers about her reproductive health, and recalled: 
"I was so glad that he made a case to the team about altering things based 
on an anecdote of a woman similar of age of me who had a very similar 
looking tumor who six years after treatment wasn't able to conceive. So he 
made that adjustment and then very much on my own through research 
and having the help of my husband who happens to be a physician in a 
very different field, I went outside of the system to try a kind of 
experimental effort to keep my ovaries on lockdown for the year to keep 
them protected from the chemo agent. [ ... ] And so I sit here today, just 
into my second trimester really feeling fortunate that these steps were 
taken because it's something that is really important to my quality oflife 
and my life plans." 
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Although treatment decisions have occurred in the past, it is important to assess a 
survivor's ability to conceive and have children as a part of their HRQoL. 
Additionally, lingering health problems may be an issue for some survivors when 
trying to conceive. One participant, for example, noted that pregnancy placed her at very 
high risk for tumor recurrence because of the nature of her meningioma. For others, their 
CNS tumor diagnosis occurred during pregnancy. In one instance, a participant had to 
abort her pregnancy because of radiation therapy. Other participants were able to bring 
their baby to term, but the months during which they were pregnant and trying to treat 
their tumor were extremely stressful and difficult because it forced them to weigh the 
health of their unborn child with their own well-being. One participant recalled: 
I didn't get the chance to go into labor. They made me, my delivery had to 
be an entire surgery because they couldn't, your body can't withstand the 
cranial pressure, having just had surgery. But since I had just had surgery, 
they were trying to not give me as much anesthesia. But anyway, it was 
huge. [ ... ]This was not how I ever pictured my first pregnancy, by any 
means. And my first pregnancy became not about me being pregnant. It 
was everything was medical. 
Although the issues raised by our participants center around choices that they made 
during treatment, they had long-lasting effects on the survivors' fertility and 
reproduction. In some instances, maternal health issues prevented survivors from having 
a baby, and in others it decreased their quality oflife during pregnancy. 
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Support Systems 
This domain examines the social support systems and resources available to 
participants. Survivors frequently cited their family and friends as a source of support 
both during their illness and afterwards. 
Social Support 
In addition to relationships with others, participants mentioned how crucial the 
social support that they received from family and friends both during their illness and 
afterwards. One participant noted: 
It has because I couldn't work for the first couple of years at all because I 
was so sick and we had to give up everything t~at we had and we had to 
move in with family because I had an infant and my husband had to 
work .. . We lost everything. We did. Because I was a teacher[ . . . ] one day 
and a brain tumor patient the next. We moved in with family and we just 
took a big step back and we stayed there for about a year or so. 
Several other participants mentioned that their parents or family continue to help them on 
a daily basis. The family support was most common among participants with children and 
participants with on-going health problems such as fatigue. Participants also mentioned 
their local communities or hometown and co-workers as a significant source of social 
support. Having the support of family, friends , co-workers, and communities seems to 
play an integral in participants' abilities to cope with their chronic conditions, and has 
improved their HRQoL. 
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Healthcare Access and Quality 
Participants had mixed feelings about the support that they received from their 
medical providers. Although several participants mentioned receiving excellent care 
during their illness, now that they were no longer being actively treated they reported 
feeling out of place when they were seen for follow-up. One participant recalled: 
"I have a doctor at [hospital name] and every time that I go in there I feel 
more stressed than when I went in. [ ... ]He [doctor] said to me, 'Not great, 
not terrible, not fabulous.' [ ... ]I called my husband and was like, 'I don't 
even know what that means!' If my cornea dries up, I lose my sight, so 
this is important. I know that he had just put some of these eye sockets 
back together and put their eye in and here I am sitting with my eye drops 
and I know I'm not a priority. He didn't even sit down. It was like, 'let's 
go, let's go.' I don't think that I belonged there and I even asked him, 'I 
don't feel like I belong here, so where should I go?"' 
Like this participant, other participants reported that their doctors were not always as 
knowledgeable or supportive as they would have liked, and that they were not satisfied 
with the care that they received. Sentiments of frustration also arose when discussing 
these medical encounters, as participants reported not feeling well-informed about their 
conditions and about survivorship. One participant noted: 
"In some ways it was the social worker in the outpatient setting where I 
saw my doc but in some ways was grounding in terms of offering some 
hope and that was really useful. She gave me some statistics about the 
important role that age plays in longer term survivorship. My doctor was 
never offering that." 
Other participants mentioned how important the information that they received from their 
medical providers was during their recovery and transition into survivorship. As one 
participant explained: 
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I'm still coming every six months and it's the same people and now we'll 
joke about it. And they'll ask about the fatigue and the vomiting and the 
balance and all of that; the usual stuff. And we'll joke and it has gotten 
better. It's good that you can see progress, but for the first two years, there 
was very, very, very little progress and that was incredibly frustrating. 
Nothing that they could do to fix it, but just hearing it come from a 
doctor's mouth, just that this isn't outside the spectrum of normal for 
cancer recovery would help. They say it now. 
These examples demonstrate how much value is placed on support and information from 
medical providers. Given that many A Y A survivors are at point when they have to 
change care providers due to moving, new health insurance, or graduation from school, it 
is important to consider the impact that the quality of their healthcare can have on their 
HRQoL. 
Overall, our qualitative fmdings support the fact that survivors of childhood CNS 
tumors often experience adverse health outcomes as a result of their tumor and the 
invasive treatments that they require. The findings also support the fact that when 
therapy-related sequelae and residual disease symptoms become chronic conditions, they 
have the potential to significantly impact an individual's function and HRQoL. 
Neurocognitive deficits typically distinguish survivors ofCNS tumors from survivors of 
other forms of solid tumors and cancer, and were prevalent within our study population. 
Physical function was also decreased in most of our population, which along with 
cognitive issues had the most significant impact on HRQoL. Our fmdings also supported 
the notion that decreased HRQoL manifest differently in the A Y A survivor population 
than in older adult or pediatric populations because of the unique life transitions that they 
are experiencing. Dating and family planning, for example are unique to the A Y A 
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population, which spans the reproductive years. Overall, neurocognitive deficits and poor 
physical health can adversely affect an A YA survivor's emotional well-being, social 
relationships, family life, career, and education. 
Current Instruments to Evaluate Health-Related Quality of Life 
Several instruments currently exist to measure HRQoL, function, and/or health 
status. Although most of the instruments are generic, meaning that they can assess 
general quality of life in both healthy and sick populations, many of them have 
supplemental modules or alternative versions that capture condition-specific aspects of 
HRQoL. A select few are cancer- or brain tumor-specific. Those instruments that 
measure function and health status often target a specific domain of quality of life, such 
as fatigue, sleepiness, and mobility. Additionally, most instruments are aimed at adults 
and children with only a few instruments designed for the A Y A population. Below are 
detailed descriptions of the instruments. Our review of existing HRQoL assessment tools, 
showed that there is currently no single instrument available to comprehensively measure 
HRQoL in A Y A survivors of childhood CNS tumors. Table 3 includes characteristics of 
the instruments. Table 4 outlines the domains ofHRQoL that were measured by the 
instruments. Below are detailed descriptions of instruments that measure HRQoL, health, 
and function. 
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Health-Related Quality of Life Instruments 
Child Health Questionnaire (CHQ): The CHQ is a set of generic instruments that can 
measure quality oflife in children ages 5 to 18 years. The CHQ consists of 87 items 
across physical and psychosocial domains. 
EORTC Core Quality of Life Questionnaire (QLQ-C30): The QLQ-C30 is a 30 item 
instrument that includes domains for physical functioning, role functioning, emotional 
functioning, cognitive functioning, social functioning, and global quality of life. In 
addition, it has individual items for fatigue, pain, nausea and vomiting, dyspnea, sleep 
disturbance, appetite loss, constipation, diarrhea, and financial impact. The QLQ-C30 has 
demonstrated retest reliability and internal validity for individuals with brain tumors and 
other forms of cancer. A Brain Cancer Module exists for supplemental co-administration 
with the QLQ-C30. 
• Brain Cancer Module (BN20): The BN20 contains 24 items across five scales: 
future uncertainty, visual disorder, motor dysfunction, communication deficit, 
and emotional distress. The BN20 also has individual items for headache, 
seizure, drowsiness, hair loss, itching, weakness of both legs, and bladder 
control. 
Euroqol EQ-5D (EQ-5D): The EQ-5D is a 17 item instrument that can be used as a 
generic HRQoL measurement tool. There are three items for each of the following 
domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
There are two remaining items ask about health status. The EQ-5D has two adult versions 
for a 5-point Likert scale and a 3-point Likert scale, and a separate instrument for youth. 
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Flanagan's Quality of Life Scale (QOLS): The QOLS is a general HRQoL instrument to 
measure QOL in people with chronic illness or healthy populations. The instrument 
contains 16 items across the dimensions of material comforts, health, relationships, 
participating in society, self, work, social/recreation, and independence. Users are asked 
to rank their satisfaction with the statement in each item on a scale of 1 to 7, with 1 being 
"Terrible" and 7 being "Delighted/Pleased." 
Functional Assessment of Cancer Therapy scale (FACT): FACT is a 28-item instrument 
designed to evaluate HRQoL in patients currently being treated for cancer. It produces 
measurements for the domains of physical health, function, social well-being, emotional 
well-being, and satisfaction with the doctor-patient relationship. FACT is a general 
measure, but can be supplemented with modules specific to treatment and disease type, 
including brain tumors. FACT has been demonstrated to be valid and reliable (Cella et 
al., 1993). 
• Functional Assessment of Cancer Therapy-Brain Tumor CFACT-Br). The 
FACT-Br subscale is designed for brain tumor patients and has 15 items. It 
includes domains for neurocognitive function, functional ability, and mobility. 
Functional Limitations Profile (FLP): The FLP is an English-language adaptation of the 
Sickness Impact Profile (SIP) instrument. The instrument is comprised of 139 items 
across the major domains of physical, psychosocial, eating, communication, and work. 
The physical domain includes the dimensions of ambulation, bodycare and movement, 
mobility, and household management. The psychosocial domain includes the dimensions 
of recreation and pastime, social interaction, alertness, sleep and rest, and emotion. 
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Health Status Questionnaire 2.0 (HSQ): The HSQ is a 39-item generic HRQoL 
instrument for adolescents and adults. The instrument focuses on measurement of 
emotional and physical health, and includes the dimensions ofhealth perception, physical 
functioning, role limitations/physical health, role limitations/emotional problems, social 
functioning, mental health, bodily pain, and energy/fatigue. The instrument also includes 
items on general health and depression. 
Health Utilities Index (HUI3): The HUB is a generic, preference-based instrument that is 
used to evaluate functional health status in survivors of childhood cancer. HUB has 45 
items across the 8 domains ofvision, hearing, ambulation, speech, pain, dexterity, 
emotion, and cognition. The HUB was developed by McMaster University in Canada, 
and there has been conflicting research regarding its validity and reliability for the 
measurement ofHRQoL in CNS tumor survivors (Glaser et al., 1999; Dlugos et al., 
2000). 
KINDL: The KINDL questionnaires were created to assess QOL in children and 
adolescents. Self-report questionnaires exist for the age groups of 4 to 7 years; 8 to 12 
years; 13 to 16 years. Proxy report questionnaires exist for children age 4 to 7 years and 8 
to 16 years. The KINDL questionnaires consist of 24 items on a Likert scale that measure 
QOL in six domains: physical, emotional, self-esteem, family, friends, school. A 
supplemental "Disease" scale can be administered along with the KINDL to cover 
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dimensions related to long-term illness or hospitalization. The Disease scale consists of a 
filter question and six single items for 1) fear/anxiety 2) depression 3) coping 4) being 
treated younger because of illness 5) hiding illness from others 6) school absences. The 
KINDL questionnaires have demonstrated discriminant validity, convergent validity, 
factorial validation, and reliability (Cronbach's a> 0.8) (Ravens-Sieberer & Bellinger, 
2000). 
Minneapolis-Manchester Quality of Life Adolescent Form (MMQL): MMQL Adolescent 
Form is a 46-item instrument that evaluates QoL through the domains of physical 
function, cognitive function, psychosocial function, body image; intimate relations, and 
outlook on life in adolescent survivors of childhood cancer. The MMQL Adolescent 
Form is completed through self-reporting, and has been demonstrated to be valid and 
reliable. Through an assessment of the MMQL Adolescent Form, Wu et al. found that 
adolescent survivors who were not on any type of therapy for their cancer had similar 
HRQoL to health controls. On-therapy patients, however, tended to report lower HRQoL 
compared to healthy controls (Wu et al., 2007). 
Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor 
(Peds-FACT-BrS): The Peds-FACT-BrS was developed to evaluate HRQoL in survivors 
of pediatric brain tumors. The instrument includes 34 items across four domains of 
physical well-being, emotional well-being and illness experiences, social well-being, and 
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brain tumor-specific concerns. The instrument has demonstrated content validity and 
reliability (Lai et al., 2007). 
Pediatric Quality of Life Inventory Measurement Model (PedsQL): The PedsQL 
Measurement Model includes a generic scale and several condition-specific modules that 
can be administered in conjunction with the generic instrument. The PedsQL 4.0 Generic 
Core Scale includes 23 items, and covers the domains of physical health, emotional 
health, social well-being, school, and psychosocial health. The PedsQL 4.0 Generic Core 
Scale can be used to evaluate HRQoL in both healthy and sick pediatric populations. 
Additionally, it is available for children age 8 to 12 years, adolescents age 13 to 18 years, 
and young adults age 18 to 25 years. PedsQL 3.0 models consist of condition-specific 
modules for asthma, arthritis/rheumatology, brain tumor, cancer, cardiac, cerebral palsy, 
end-stage renal disease, diabetes, fatigue, and pain. The PedsQL Measurement Model4.0 
and its related condition-specific modules have been demonstrated to be internally 
reliable and valid (Varni & Limbers, 2009; Palmer et al., 2007) and is reliable and valid 
for self-reporting by children as young as age 5-years (Varni et al., 2007). 
• Peds QL Brain Tumor Module. The brain tumor module has 24 items across 
six scales: Cognitive Problems, Pain and Hurt, Movement and Balance, 
Procedural Anxiety, Nausea, and Worry. 
• Peds QL Cancer Module. The cancer module has 27 items across eight scales: 
Pain and Hurt, Nausea, Procedural Anxiety, Treatment Anxiety, Worry, 
Cognitive Problems, Perceived Physical Appearance, and Communication. A 
modified version ofboth the generic and cancer module scales exists for A YA 
patients (Ewing et al., 2009). 
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• Peds QL Multidimensional Fatigue Scale. The multidimensional fatigue scale 
has 18 items across three scales: General Fatigue Scale, Sleep/Rest Fatigue 
Scale, and Cognitive Fatigue Scale. 
• PedsQL 4.0 Young Adult Qualitv of Life Inventory. This instrument contains 
23 items across 4 domains: health and activities, feelings, getting along with 
others, and work/studies. 
Quality of Life-Cancer Survivors (QOL-CS): The QOL-CS was developed to evaluate 
quality of life in cancer survivors. The QOL-CS has 41-items; includes domains for 
physical well-being, psychological well-being, social well-being, spiritual well-being; 
and has sub-scales for fears and distress. 
Short Form 36 Health-Status Survey (SF-36): The SF-36 was developed as part of the 
Medical Outcomes Study conducted by RAND. The SF-36 is a generic quality of life 
instrument consisting of 36 items across eight dimensions: physical functioning, role 
limitations due to personal or emotional problems, role limitations due to physical 
problems, emotional well-being, social functioning, pain, energy/fatigue, and general 
health perceptions. There is also a single item for perceived health change. The SF-36 is 
valid and reliable. 
TNO-AZL Questionnaire for Adult's Health-Related Quality of Life (TAAQOL): The 
T AAQOL instrument measures quality of life in individuals age 16 years and older. The 
instrument consists of 45 items across 12 domains of gross motor function, fine motor 
function, cognitive function, sleeping, pain, social well-being, activities of daily living, 
sexuality, vitality, happiness, depressive moods, and aggressiveness. 
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World Health Organization Quality of Life (WHOQOL-100): The WHOQOL-100 was 
designed as a generic HRQoL instrument by the World Health Organization's Division of 
Mental Health. The assessment tool includes 100 items across the domains of physical 
health, psychological, social relationships, level of independence, environment, and 
spirituality/religion/personal beliefs. The instrument produces scores for the four domains 
of: physical health, psychological, social relationships, and environment. 
Health and Function Instruments 
Barthel Activities of Daily Living Index (BADLI): The Barthel Index consists of 10 items 
that measure an individual's ability to perform activities of daily living (ADLs) and 
assess mobility. 
Epworth Sleep Scale: The Epworth Sleep Scale measures excessive daytime sleepiness 
through a set of 8 items. Excessive daytime sleepiness is indicative of fatigue and energy 
level. 
Perceived Illness Experience Scale (PIE): The PIE scale was designed to assess the 
perceived effects of illness on children. The scale can be completed by self-report or 
proxy. The PIE contains 34 items across the 10 domains of physical appearance, 
interference with activities, peer rejection, integration in school, manipulation, parental 
behavior, disclosure, preoccupation with illness, food, and treatment. 
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Profile of Mood State (POMS): POMS is a 65-item instrument that evaluates affective 
status in adults. The POMS includes subscales for tension-anxiety, anger-hostility, 
fatigue-inertia, depression-dejection, vigor-activity, and confusion-bewilderment. The 
POMS is measured via self-report and takes approximately 5 to 10 minutes to complete. 
A brief version of the POMS exists and there is a specific POMS for people with bipolar 
disorder. 
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QUEST CNS Instrument 
Content validity ratios were determined for all items sent to the expert panel. 165 
items were eliminated on the basis ofCVR: 22 Social Health and Well-Being, 19 
Physical Health and Well-Being, 19 Mental Health and Well-Being, 8 Cognitive 
Functioning, 24 Health Behavior, 20 Reproduction and Sexual Health, 24 Support 
Systems, and 29 Other. The items that were retained after CVR analysis are shown in 
Table 5. 
Table 5 Retained items and corresponding content validity ratios 
Physical health and well-being 
I live independently 
I have difficulty controlling my weight 
I am in physical pain 
I have difficulty taking care of myself 
I rely on others for help with physical tasks 
I am too tired to do what I want to 
I have low energy 
I have difficulty sleeping 
My pain impedes my ability to function 
I take a nap during the day 
I lose my balance easily 
I have difficulty engaging in physical activity 
I have difficulty seeing 
It is difficult for me to hear 
I take medication for headaches 
I take medication for my tumor 
I am healthy 
I sleep too much 
I tire easily 
I have headaches 
My pain affects my quality oflife 
I have seizures 
It is difficult to do manual tasks 
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CVR 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
It is difficult to use my hand 
My seizures are well controlled 
I do not drive 
I have poor coordination 
My vision is worsening 
My hearing is worsening 
I take medication for seizures 
I take medication for pain 
I am being treated for my tumor 
I have had a relapse of my tumor 
I have regular follow-ups with my doctor 
I have regular MRls 
My health is deteriorating 
Social health and well-being 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
I have close personal relationships 1 
I worry about dating or being with someone long-term 
I am married 1 
It is difficult for me to date 1 
I have strong social support from friends 1 
I worry about how people will feel about me after they learn about my 
tumor 1 
I feel comfortable talking about my experience with others 0.75 
I worry about having children 0.75 
I have strong social support from my significant other 0.75 
I do not date 0.75 
I have strong social support from family 0.75 
People forget that my tumor still affects me 0.75 
Mental health and well-being 
I feel depressed 1 
My health affects my life 1 
I feel anxious 1 
I feel withdrawn 1 
I worry about my health 1 
I have difficulty managing my anger 1 
I worry that my tumor will return 1 
l feel sad 1 
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I feel optimistic about my future 
I worry about my health in the future 
I do not like the way my body looks 
I feel lonely 
I feel helpless 
I like to live life to the fullest 
I engage in risky behavior 
I feel angry 
I feel insecure about my future 
I worry about my tumor 
I feel frustrated 
I am moody 
I worry about my medical bills 
I am embarrassed by my body 
I feel embarrassed about my tumor 
I am comfortable with my weight 
I feel in control of my life 
I have strong emotional support from friends 
I feel alone 
I feel inadequate 
I feel in control of my health 
I have feelings of guilt 
I have strong emotional support from family 
I feel guilty about being dependent on other people 
I feel happy 
I feel satisfied with my life 
I feel anxious when I go to the doctor 
I avoid going to the doctor 
Cognitive functioning 
I worry about my performance at work 
I worry about my performance in school 
I am forgetful 
I have a bad long term memory 
I have a bad short term memory 
I have difficulty following instructions 
I have difficulty multi-tasking 
I have difficulty reading 
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1 
1 
1 
1 
1 
1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
I have difficulty remembering directions 
I have trouble doing math 
I have trouble understanding concepts 
I have trouble with spatial tasks 
I need to take frequent breaks when I study 
Health behavior 
I worry about how much I drink 
It is difficult for me to walk 
I have a normal appetite 
It is difficult for me to run 
I have difficulty eating 
I monitor my weight and diet 
I have difficulty swallowing 
I drink alcohol 
I feel motivated to exercise regularly 
I use recreational drugs 
I drink often 
I have difficulty exercising 
I exercise regularly 
I currently smoke 
I drink more than two times per week 
I am in good physical shape 
I have difficulty participating in sports 
I am on a restricted diet 
Sexual and reproductive health and well-being 
I am sexually active 
I engage in risky sexual behavior 
I have fertility problems 
I worry about my long-term ability to parent 
Support systems 
I communicate well with my doctor/care team 
My doctor listens to me 
I feel rushed when I speak with my doctor 
I receive academic accommodations from my school 
I live with my parents 
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0.75 
0.75 
0.75 
0.75 
0.75 
1 
1 
1 
1 
1 
1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
1 
1 
1 
1 
1 
I live with non-immediate family members 
I can no longer live on my own 
I have very strong family support 
My spouse/partner is very supportive of me 
I feel supported by my medical care providers 
My medical providers support me well 
I understand my medical treatment options 
My medical providers communicate well with me 
My medical providers respond to my health concerns 
My doctor explains my medical treatment options to me 
I have difficulty obtaining life insurance 
My employer is supportive of my health needs 
I have health insurance 
School is accommodating of my health 
I worry about financing my medical care 
I receive peer support from other people with tumors 
I find peer support from other patients to be helpful 
Other 
I use acupuncture 
I use alternative medicine 
I take naps in order to maintain my energy 
I have memory loss 
I have a guide dog 
I have good relationships with others 
I feel hopeful 
My tumor has changed my personality 
I have difficulty keeping up with school work 
My lack of hormones affects my quality of life 
I am very organized 
I feel positive about life 
I am optimistic 
I use a cane 
I have a good quality of life 
I have good eyesight 
I take hormone replacements regularly 
My tumor has changed my life perspective 
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1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
Development of the Final Instrument 
The final QUEST CNS instrument will be produced from the items listed in Table 
5. The final instrument will then undergo cognitive testing with 10 to 15 CNS survivors. 
The survivors will be recruited from the same set of potential participants who were 
mailed initial letters for recruitment and who did not already opt out of the study. Testing 
will be conducted by the study's psychologist and research associate at Massachusetts 
General Hospital. Each participant will be given the full set of QUEST CNS items, and 
will be asked to comment on: 1) what the question means to them, 2) how they framed 
their answer, and 3) whether they think there is equal distance between the responses in 
the scale. The information gathered from the cognitive testing will be used to further edit 
the QUEST CNS instrument. After completion of the study period, we plan to conduct 
pilot tests and assess the psychometric properties of the fmal QUEST CNS tool. 
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DISCUSSION 
This study sought to develop a qualitative instrument to measure HRQoL in A Y A 
survivors of childhood CNS tumors. The instrument's development was informed by 
focus group discussions with CNS tumor survivors and consultation with experts in the 
field of oncology/hematology and psychology. Our findings from the focus groups 
provide an inventory of the disease symptoms, treatment sequelae, and HRQoL issues 
that A Y A survivors of CNS tumors may face. The major domains identified in our study 
correspond with existing literature about the long-term impact of CNS tumor 
survivorship on HRQoL. Additionally, our examination of existing HRQoL instruments 
demonstrates the need to develop a tool specifically for the A Y A CNS tumor survivor 
population, as this group has unique needs and disease symptoms/treatment sequelae not 
shared by groups of pediatric and adult survivors and by survivors of other types of 
cancer. 
The development of a HRQoL instrument for use within the A Y A population of 
CNS tumor survivors will be beneficial for both current CNS tumor patients and 
survivors. HRQoL measurement can enhance provider-patient communication, facilitate 
care decisions, improve the appropriateness and adequacy of medical care, and provide 
current CNS tumor patients with long-term outlook information. For A Y A survivors 
specifically, an instrument such as QUEST CNS enables longitudinal surveillance of their 
HRQoL, which can improve their long-term health outcomes by enabling their providers 
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to better address their needs and identify any changes in health status, function, and well-
being. 
A major limitation of this study is the small study population and the 
homogeneity within it. All participants were English-speaking and received care at a 
single institution. Additionally, we had to restrict our study population by age to ensure 
that our results reflected the experiences of A Y A survivors. Similarly, we did not include 
parents and patient proxies in our study, which may have eliminated those survivors who 
were not healthy enough to travel and participate in the study independently. The 
limitations of our study are demonstrated by the fact that several issues we expected to 
see from the literature did not arise during our focus group discussions. Difficulty 
obtaining health insurance, for example, did not arise during our focus group discussions. 
Therefore, it is likely that our findings do not represent the entire spectrum of experience 
for A Y A survivors of CNS tumors. 
The intent of this study was to produce an in-depth exploration of the major 
HRQoL domains for A Y A survivors of childhood CNS tumors and to develop a HRQoL 
assessment tool from these fmdings. From the focus groups, we were able to create a list 
of potential items for inclusion in our QUEST CNS instrument, and that list was pared 
down with additional input from professional experts. After fmalization of the 
instrument, future studies of QUEST CNS should be conducted to ensure content validity 
and test-retest reliability. In addition to psychometric testing, piloting of the instrument 
should be conducted with the goal of refining the instrument. These studies should be 
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conducted with survivors at varying functional levels in order to ensure validity and 
applicability across the heterogeneous experiences of the A Y A survivor population. 
Although the findings and products of this study are preliminary, they provide 
valuable insight into the A Y A survivor experience for individuals with pediatric CNS 
tumors. The experiences of our focus group participants and the opinions of our expert 
panel corresponded with the literature regarding the unique needs ofthe AYA survivor 
population and the health and function of CNS tumor survivors. Due to the limitations of 
the study sample, it is likely that our findings reflect the experiences of survivors who 
function at a high level, as all lived independently and did not have significant role 
restrictions within their personal and professional lives. In refining the QUEST CNS 
instrument it will be important to incorporate the experiences of those survivors with 
more severe morbidities. 
In conclusion, survivors of childhood CNS tumors are a unique population both 
due to the low overall prevalence of their disease and the neurocognitive, psychosocial, 
and physical sequelae that they are at risk for experiencing. Due to the benign nature of 
many CNS tumors and the distinct survivor experiences of this population, CNS tumor 
survivors do not always benefit from the significant efforts of researchers and 
communities who address the needs of cancer survivors. In the area of HRQoL 
assessment, there has been limited progress in creating an instrument to accurately and 
comprehensively capture the experiences ofCNS tumor survivors. Ofthe instruments 
that do exist, none of them are tailored to the A Y A age group, which faces different 
social and professional challenges than children and older adults. Our development of the 
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QUEST CNS tool seeks to fill this gap in HRQoL measurement, with the ultimate goal of 
improving health outcomes and HRQoL for current and future A Y A survivors of CNS 
tumors. 
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APPENDIX A 
Focus Group Guide 
1. Tell participants thanks for coming and give them an overview of the project. Hand out name tags and 
handouts at this time. 
Thank you for joining our focus group. My name is _ _ _ and I am part of ___ . (Give a little 
background about yourself and other staff that are present.) As you know, we've brought you all together 
today because you are all young adult survivors of CNS tumors. We are interested in learning about the 
unique ways that this experience has influenced your daily life. 
However, before we begin our discussion, we want to go over a few brief points: 
As we mentioned in our calls to each of you, this conversation is being tape recorded to make sure that we 
remember everything that you say. Your answers are really important to us and so we would like to record 
them to make sure we don't miss anything. We plan to share a summary of what we have learned from you 
with clinical staff, but your identity will be protected at all times. Your names will never be identified or 
linked to your comments in any way. We know that you may have both positive and negative things to 
share and it is important for us to know about both. Regardless of what you say, the care that your family 
receives will not be negatively affected in any way. Hopefully, we will be able to make some important 
improvements as we learn from your suggestions and feedback. Is this all right? 
In order to have an effective and respectful focus group, please give your attention to the person who is 
speaking and please avoid having side conversations. In order to respect your privacy, we ask that you 
consider all of the information that is shared here as confidential. Please do not share the specifics of this 
discussion with others after you leave this room. 
The last thing that we'd like to tell you is that we really want to know what each of you think. There are no 
right or wrong answers to any of the questions we will ask you. You all have a lot of different ideas and 
experiences, and we want to hear about them. Make sure that you stop us if we say something that doesn't 
make sense or if you have questions about anything. 
2. Do participant introductions. 
We'd like to get started by having everyone introduce themselves. Please let us know what you would like 
us to call you and tell us a bit about yourself 
3. Give a brief definition of HR.QoL, explaining its significance and relevance in the context of CNS tumor 
survivorship. 
Health-related quality of life is a measure of health and well-being that assesses how an individual's health 
status influences his or her daily life. In evaluating many different aspects of health, HRQoL assessment 
tools measure an individual's ability to engage in typical daily activities. In addition to physical and mental 
health, an HRQoL tool may measure health aspects such as emotional functioning, social well-being, and 
cognitive functioning. 
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As cancer survival rates have steadily risen, measuring the long-term effects of cancer and its treatments 
has become increasingly important. Health-Related Quality of Life tools have come to be recognized as 
some of the most comprehensive and significant measures of such long-term outcomes. In this study, we 
hope to learn more about the quality of life of young adult CNS tumor survivors like yourselves. Although 
there are many HRQoL tools designed for cancer patients and survivors, and some that are specific to CNS 
tumors, there are no HRQoL tools in existence that focus on AYA survivors and long-term survivorship 
issues. Through this study, we hope to fill this gap and take the first steps towards creating a HRQoL 
evaluation tool that specifically addresses the unique issues faced by AYA survivors ofCNS tumors. 
4. Briefly explain how focus groups fit into the project as a whole. Discuss what we hope to achieve 
through the groups and provide a description of what participation in the focus groups entails . Also include 
information about the other 5 focus groups. 
This focus group will last about 90 minutes and is 1 of 6 groups that we are holding with CNS tumor 
survivors here at MGH. All of these focus groups will be participating in the same activities that we do 
today; the only difference between these groups is the age of the participants. The input that we receive 
from you today, along with the input that we receive from the 5 other focus groups, will help us identify the 
domains and questions that are most important to include in our AYA CNS-specific HRQoL tool. Input 
from relevant clinicians will also be used to craft this HRQoL measure. Ultimately, we hope that this 
HRQoL tool will be used to help physicians and researchers better target their treatment efforts and to help 
measure the efficacy of clinical trials. 
5. Begin focus group activities. 
A. Ask participants to think about all the ways that their cancer and its treatment has affected their 
quality of life. Allow each individual to take a turn sharing his or her point of view. Facilitators 
should keep a list of specific items mentioned. 
Now we 'd like you to describe the ways that your CNS tumor and its treatment has affected (and continues 
to affect) your life. For example, the effects of the tumor or its treatment may interfere with your ability to 
concentrate or to sleep well. Alternatively, your experience may exercise some positive effects on your life, 
such as helping you keep a positive outlook on certain things. This is meant to be a brainstorming exercise, 
so please feel free to talk about ANY of the ways having and being treated for a CNS tumor has affected 
your life. You can draw from your own experience, or the experiences of your peers. 
B. Now ask the group to consider broad domains of quality of life that CNS-tumor survivorship 
might influence. Use the list of specific items discussed in activity A to prompt participants. 
Consider broad HRQoL domains used elsewhere (Physical Functioning, Emotional Functioning, 
Social Functioning, School Functioning, etc.- we can create a uniform list of domains to go over). 
So far, the following items have been listed as ways that CNS tumors and treatments affect daily life: 
(Briefly recap the points that have been recorded by the facilitator.) What broad domains do you think that 
these issues should be categorized under? (Define domain if necessary.) Is there anything else that anyone 
would like to add to this list? 
C. Once participants are finished listing domains, ask them to generate specific questions that should 
fall under these domains. 
Now that we have a list of domains for an AYA CNS-specific HRQoL tool, we'd like your opinion on the 
specific questions that should go under these domains. So let's start with (choose a 
domain). Can anyone think of some questions that are important to include here? 
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D. Toward the end of the conversation, after subjects are finished coming up with their own 
categorizations, List domains that are on existing HRQoL tools that haven't already been 
mentioned. Prompt subjects to think about these domains and what things might fall under them. 
Now I'm going to share some general categorizations that appear on existing HRQoL tools. I'd like you to 
think about these domains and whether or not you think that they are relevant to CNS tumor survivorship. 
For those domains that you find to be relevant, please share any questions that you think should fall under 
this category. 
E. Once participants are completely finished voicing their ideas, begin to wrap up the meeting. Have 
participants fill out stipend forms, validate their parking, and give them the chance to ask any 
questions that they might have. Then thank participants and send them on their way. 
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APPENDIXB 
Detailed Coding Scheme 
Domain/Code Definition 
A)Socia/ Functionin!f 
1) Peer groups and friendships Effect on the relationship 
2) Romantic/Spousal relationshiQ_s Effect on the relationship 
3) Relationship with family members Including children, immediate and 
extended family 
4) Stigma External reactions (may appear with, but 
not to be confused with body image or self 
esteem codes) 
5) Social activities Ability to perform social activities (could 
be a physical, emotional or other cause) 
6) Connection/Shared experience with other patients Also for other chronic illnesses 
B) Physical Functionin!f 
1) Physical limitations on ADL (activities of daily Eg. Driving, hygiene, caring for self (list of 
life) ADL here: ) 
2) Sleep 
3) Fatigue 
4) Weight fluctuation 
5) Pain 
6) Headaches 
7) Seizures 
8) Balance, coordination or motor skills 
9) Sensory issues 
10) Medications/side effects, follow-up, MRis 
11) Second cancers and relapse Not talking about fear of relapse and the 
effect that it would have on life 
C) Emotional Functioning and Mental Health 
1) Depression, anxiety, suicidal ideation More severe or clinical 
2) Anger or aggression 
3) Stress, worry or frustration Less severe or more anecdotal 
4) Feeling unsure about future 
5) Body image Not just the statement of changes in 
physical appearance, but an indication of 
the individual feeling embarrassed or 
uncomfortable about appearance. 
6) Feelings regarding self-esteem Includes feelings of not living up to one's 
potential or not contributing to society 
7) Feelings of isolation or loneliness 
8) Helplessness/empowerment 
9) Independence versus dependence on family or 
others 
10) Guilt 
11) Changed outlook on life or personality, Includes desire to do community service, 
motivation to help others help improve treatment of tumors, etc. 
12) Feelings about medical facilities or procedures Showing reaction/fear towards facilities or 
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procedures, not an assessment of the 
treatment itself 
D) School and Work Functioning 
1) Productivity or performance in school or work 
2) Effect on decisions/direction of work/career or 
school 
3) Moving 
E) Cognitive Functioning 
1) Memory 
2) Other executive functioning issues Multitasking, word replacement, learning 
ability, etc. 
3) Mathematics or reading comprehension 
4) Spatial reasoning issues Getting lost, not being able to drive b/c of 
directions 
F) Sexual and Reproductive Functioninf! 
1) Risky sexual behavior 
2) Sexual Activity 
3) Libido 
4) Fertility or pregnancy issues 
5) Decisions about parenthood or effect on 
parenting 
G) General Impact on Functioninf[ 
• 'G' should be used when an ambiguous comment is made about how a person is 
doing/functioning that cannot be clearly categorized as Physical or Emotional 
Functioning. ln other words, 'G' should not be double coded with Physical or Emotional 
Functioning unless it is a very unique piece of text. 
• G' should only be used when the subject expands vaguely on how they're 
doing/functioning. For example, it should not be used for only "my quality oflife is 
good." Or "I feel lucky." It must have some greater effect or reflection attached. 
• Examples 
0 " .. . And I'm just feeling more and more grateful. I feel like at the time I might 
not have really noticed that. 1 felt like I had a lot of symptoms after my surgery 
and my recovery was hard for me, but I'm doing so much better than these 
clients that I have and 1 feel like every time I see them, "wow, this is so hard for 
them." 
0 "Sometimes I think you just have to be aware that I have a lower functioning 
level at certain days." 
H) Health Behaviors 
l) Use of tobacco, alcohol recreational drugs, etc. Alcohol, drugs, tobacco 
2) Physical activity or exercise 
3) Diet and nutrition habits 
4) Cautious behavior or risk taking Doing/not doing certain things because of 
worries about physical health 
I) Support Svstems 
I) Family or friend support Use when expressly describes support/help 
& NOT THE SAME as social effects on 
fam/friends 
2) Medical support or feedback to providers 
3) Insurance support 
4) Work support 
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5) School support 
6) Access to community supports and services 
7) Moving/relocating 
J) Other 
1) Spirituality 
2) Interaction with the legal system 
3) Impact of diagnosis on other people 
4) Alternative medicine 
5) Coping or compensatory mechanisms 
6) Positive effects or outlook 
7) Reflections on type of tumor 
8) Gender specific issues Unrelated to sexuality and fertility issues 
9) Age related issues 
10) Tumor v. Cancer 
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